PARG inhibitors

Abstract

This disclosure provides certain compounds for use as inhibitors of PARG (polyADP-ribose glycohydrolase) activity. This disclosure also relates to methods for preparing these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of cancer and other diseases, the compounds having a structure as shown in formula (IA).

Description

PARG inhibitors

[0001] This application claims priority to Chinese Patent Application No. 2023114041256 filed on October 26, 2023, Chinese Patent Application No. 2023115667661 filed on November 22, 2023, Chinese Patent Application No. 2024100209152 filed on January 5, 2024, Chinese Patent Application No. 2024102516704 filed on March 5, 2024, Chinese Patent Application No. 2024107836041 filed on June 17, 2024, Chinese Patent Application No. 2024112921468 filed on September 13, 2024, and Chinese Patent Application No. 2024114656236 filed on October 18, 2024. The entire contents of the aforementioned Chinese patent applications are incorporated herein by reference. Technical Field

[0002] The present disclosure relates to certain compounds that are useful as inhibitors of PARG (poly ADP-ribose glycohydrolase) activity. The present disclosure also relates to methods for preparing these compounds, to pharmaceutical compositions containing them, and to their use in treating cancer and other diseases. Background Art

[0003] Maintaining genomic stability and integrity is essential for the normal function of cells. DNA damage can easily occur due to external environmental factors or internal factors. Therefore, the body has a complex set of DNA damage repair (DDR) mechanisms to promptly and accurately repair DNA damage. Defects in these mechanisms can easily lead to genomic instability, cell apoptosis, and even cancer.

[0004] The clinical success of PARP (Poly ADP-Ribose Polymerase) inhibitors has triggered a wave of drug development in the industry targeting DNA damage repair pathways and using synthetic lethality as a mechanism of action. PARP1 / 2, as poly ADP-ribose enzymes, are key proteins involved in DNA damage repair. Inhibiting the enzymatic activity of PARP1 / 2 will cause cells to produce a large number of single-strand DNA breaks, which then develop into double-strand breaks. In cancer cells with defects in DNA homologous recombination repair, these double-strand DNA breaks cannot be repaired normally, ultimately leading to the death of cancer cells. Therefore, there is a synthetic lethal effect between PARP1 / 2 and genes related to DNA double-strand damage repair (mainly homologous recombination repair).

[0005] PARG (Poly ADP-Ribose Glycohydrolase) is the most important poly ADP-ribose hydrolase in cells, responsible for over 90% of poly ADP-ribose hydrolysis. It hydrolyzes the poly ADP-ribose chains produced by PARP. Although PARG and PARP have opposite functions as target proteins, both play important regulatory roles in DNA damage repair and replication stress. When DNA is damaged, PARP is recruited to the site of damage and catalyzes the formation of poly ADP-ribose chains. These branches then serve as platforms for recruiting other DNA repair factors to aid in the repair of the DNA damage site. After DNA repair, PARG hydrolyzes these ADP-ribose branches, completing the repair cycle. Conversely, the relentless proliferation of cancer cells creates replication stress, necessitating the pausing of DNA replication forks to repair DNA damage near the forks. During this process, cells also need to recruit PARP at the paused replication fork. Through the rapid synthesis of its own poly(adenosine diphosphate)-ribose branched chains, it inhibits the activity of the RECQ1 enzyme that promotes replication fork restart, while recruiting a series of repair factors to complete DNA damage repair. After the repair is completed, PARG will rapidly hydrolyze the poly(adenosine diphosphate)-ribose branched chains, promoting the release of PARP from the paused replication fork and restoring the enzymatic activity of RECQ1 to restart replication. Knocking out PARG in cells will aggravate replication stress and DNA damage. Therefore, PARG has the potential to act as a synthetic lethal target to act on tumors with DNA damage repair defects or under replication stress.

[0006] Given the similarities in biological function between PARG and PARP, PARG inhibitors, like PARP, have the potential to treat tumors with BRCA gene defects or even homologous recombination deficiency (HRD). Furthermore, PARG also exhibits synthetic lethality with replication stress-related genes, making PARG inhibitors potentially effective in treating tumors with replication-related gene defects.

[0007] Among the PARG inhibitors currently under development, few are in the clinical stage and most are in the early stages of development. Therefore, the development of a new class of PARG inhibitors is of great research significance.

[0008] Summary of the Invention

[0009] The present disclosure aims to provide a novel class of compounds having PARG inhibitory activity, pharmaceutical compositions containing the compounds, useful intermediates for preparing the compounds, and uses of the compounds in preparing drugs for treating cancer.

[0010] The present disclosure provides a compound represented by formula (IA) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0011] in,

[0012] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxyl, -NR n1 R n2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0013] x 2 Selected from CR x2 、N、C(=O)、C(=CR x2 ), where R x2 Selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR n1 R n2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0014] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxyl, -NR n1 R n2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0015] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxyl, -NR n1 R n2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0016] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxyl, -NR n1 R n2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0017] x 6 Selected from CR x6 、N、C(=O)、C(=CR x6 ), where R x6 Selected from H, halogen, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR n1 R n2 、-C 1-6 Alkoxy C1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd Wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0018] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxyl, -NR n1 R n2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0019] x 8 Selected from N, O, CR x8 , CR x8 Rx8 NR x8 、S(O) p 、C(=O)、C(=CR x8 ), where R x8 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR n1 R n2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1- 6 alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、-S(O) p R ba 、-N=S(O)R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0020] or two R's attached to the same carbon x8 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl or 3 to 8-membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0021] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 、C(=CR x8 ), where R x9 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR n1 R n2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)Rba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0022] or two R's attached to the same carbon x9 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl and 3 to 8-membered heterocyclic group are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 Ra2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0023] or R x8 With R x9 and the atoms to which it is connected together form a 3 to 7 membered ring; the 3 to 7 membered ring is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , deuterated C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n1 R n2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0024] is a single bond or a double bond;

[0025] R a 、R d and R e are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR n1 R n2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0026] or R a 、R d and R e Any two atoms to which they are connected together form a 3- to 8-membered cycloalkyl, a 3- to 8-membered heterocyclyl, a 6- to 10-membered aryl, and a 5- to 10-membered heteroaryl; wherein the 3- to 8-membered cycloalkyl, the 3- to 8-membered heterocyclyl, the 6- to 10-membered aryl, and the 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0027] W is selected from

[0028] Ring B is selected from 3- to 10-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 5- to 7-membered monoheterocyclyl, 7- to 12-membered spiroheterocyclyl, 6- to 10-membered bridged heterocyclyl, and 6- to 10-membered fused heterocyclyl;

[0029] Each R b are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR n1 R n2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O) p NR be R bf and S(O) p R ba ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1- 6-membered alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NRbc1 R bd1 , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0030] R n1 、R n2 、R a1 、R a2 are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, amino, nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0031] R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Deuterated alkoxy, C 1-6 alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, -OR f 、-C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0032] or R n1 With R n2 、R a1 With R a2 、R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group; the 3-7 membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0033] Ring C is selected from 3- to 10-membered cycloalkyl, 3- to 10-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0034] Each R c are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR n1 R n2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0035] R ba1 、R bb1 、R bc1 、R bd1 、R be1 、R bf1 、R ba2 、R bb2 、R bc2 、R bd2 、Rbe2 、R bf2 are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 deuterated alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, -NR a1 R a2 、-OR f , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0036] R f Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1- 6 alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C1-6 The alkyl group is substituted by one or more substituents;

[0037] n is selected from 0, 1, 2 or 3;

[0038] m is selected from 0, 1, 2 or 3;

[0039] p is selected from 0, 1 or 2.

[0040] The present disclosure provides a compound represented by formula (IA) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0041] in,

[0042] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0043] x 2 Selected from CR x2 、N、C(=O)、C(=CR x2 ), where R x2 Selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0044] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0045] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0046] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0047] x 6 Selected from CR x6 、N、C(=O)、C(=CR x6), where R x6 Selected from H, halogen, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0048] x 7 Selected from C, CR x7 , N, where Rx7 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0049] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p 、C(=O)、C(=CR x8 ), where R x8 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1- 6 alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、-S(O) p R ba 、-N=S(O)R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 Ra2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0050] or two R's attached to the same carbon x8 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl or 3 to 8-membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0051] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 、C(=CR x8 ), where R x9 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR b1 R b2 , cyano, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0052] or two R's attached to the same carbon x9 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl and 3 to 8-membered heterocyclic group are optionally selected from deuterium, halogen, C 1-6Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0053] or R x8 With R x9 and the atoms to which it is connected together form a 3 to 7 membered ring; the 3 to 7 membered ring is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , deuterated C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl, wherein the 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR b1 R b2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0054] is a single bond or a double bond;

[0055] R a 、R d and R e are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0056] or R a 、R d and R e Any two atoms to which they are connected together form a 3- to 8-membered cycloalkyl, a 3- to 8-membered heterocyclyl, a 6- to 10-membered aryl, and a 5- to 10-membered heteroaryl; wherein the 3- to 8-membered cycloalkyl, the 3- to 8-membered heterocyclyl, the 6- to 10-membered aryl, and the 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0057] W is selected from

[0058] Ring B is selected from 3- to 10-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 5- to 7-membered monoheterocyclyl, 7- to 12-membered spiroheterocyclyl, 6- to 10-membered bridged heterocyclyl, and 6- to 10-membered fused heterocyclyl;

[0059] Each R b are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O) p NR be R bf and S(O) p R ba ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1- 6-membered alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0060] R b1 、R b2 、R a1 、R a2 are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)ORbb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, amino, nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0061] R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Deuterated alkoxy, C 1-6 alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, -OR f 、-C(O)R ba1 、S(O)p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0062] or R b1 With R b2 、R a1 With R a2 、R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group; the 3-7 membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0063] Ring C is selected from 3- to 10-membered cycloalkyl, 3- to 10-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0064] Each R c are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C1-6 The alkyl group is substituted by one or more substituents;

[0065] R ba1 、R bb1 、R bc1 、R bd1 、R be1 、R bf1 、R ba2 、R bb2 、R bc2 、R bd2 、R be2 、R bf2 are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 deuterated alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, -NR a1 R a2 、-OR f , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0066] R f Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1- 6 alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0067] n is selected from 0, 1, 2 or 3;

[0068] m is selected from 0, 1, 2 or 3;

[0069] p is selected from 0, 1 or 2.

[0070] The present disclosure provides a compound represented by formula (IA) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0071] in,

[0072] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0073] x 2 Selected from CR x2 、N、C(=O)、C(=CR x2 ), where R x2 Selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) pNR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0074] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0075] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0076] x 5 Selected from C, CRx5 , N, where R x5 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0077] x 6 Selected from CR x6 、N、C(=O)、C(=CR x6 ), where R x6 Selected from H, halogen, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NRbe R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0078] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0079] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p 、C(=O)、C(=CR x8 ), where R x8 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1- 6 alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0080] or two R's attached to the same carbon x8 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl or 3 to 8-membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0081] x 9 Selected from CR x9 、N、O、NRx9 、S(O) p , CR x9 R x9 、C(=CR x8 ), where R x9 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0082] or two R's attached to the same carbon x9 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl and 3 to 8-membered heterocyclic group are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0083] or R x8 With R x9 and the atoms to which it is connected together form a 3 to 7 membered ring; the 3 to 7 membered ring is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be Rbf 、-C(O)OR bb 、-C(O)NR bc R bd , deuterated C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0084] is a single bond or a double bond;

[0085] R a 、R d and R e are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0086] or R a 、R d and R e Any two atoms to which they are connected together form a 3- to 8-membered cycloalkyl, a 3- to 8-membered heterocyclyl, a 6- to 10-membered aryl, and a 5- to 10-membered heteroaryl; wherein the 3- to 8-membered cycloalkyl, the 3- to 8-membered heterocyclyl, the 6- to 10-membered aryl, and the 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0087] W is selected from

[0088] Ring B is selected from 3- to 10-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 5- to 7-membered monoheterocyclyl, 7- to 12-membered spiroheterocyclyl, 6- to 10-membered bridged heterocyclyl, and 6- to 10-membered fused heterocyclyl;

[0089] Each R bare the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O) p NR be R bf and S(O) p R ba ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1- 6-membered alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0090] R b1 、R b2 、R a1 、R a2 are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, amino, nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0091] R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Deuterated alkoxy, C 1-6 alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, -OR f 、-C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0092] or R b1 With Rb2 、R a1 With R a2 、R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group; the 3-7 membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0093] Ring C is selected from 3- to 10-membered cycloalkyl, 3- to 10-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0094] Each R c are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0095] R ba1 、R bb1 、R bc1 、R bd1 、R be1 、R bf1 、R ba2 、R bb2 、R bc2 、R bd2 、R be2 、R bf2are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 deuterated alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, -NR a1 R a2 、-OR f , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0096] R f Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1- 6 alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0097] n is selected from 0, 1, 2 or 3;

[0098] m is selected from 0, 1, 2 or 3;

[0099] p is selected from 0, 1 or 2.

[0100] The present disclosure provides a compound represented by formula (IA) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0101] in,

[0102] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0103] x 2 Selected from CR x2 、N、C(=O)、C(=CR x2 ), where R x2 Selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0104] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0105] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0106] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0107] x 6 Selected from CR x6 、N、C(=O)、C(=CR x6), where R x6 Selected from H, halogen, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0108] x 7 Selected from C, CR x7 , N, where Rx7 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0109] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p 、C(=O)、C(=CR x8 ), where R x8 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1- 6 alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2- 6-alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)Rba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0110] or two R's attached to the same carbon x8 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl or 3 to 8-membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0111] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 、C(=CR x8 ), where R x9 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1- 6-alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0112] or two R's attached to the same carbon x9 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl and 3 to 8-membered heterocyclic group are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0113] or R x8 With R x9 and the atoms to which it is connected together form a 3 to 7 membered ring; the 3 to 7 membered ring is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0114] is a single bond or a double bond;

[0115] R a 、R d and R eare the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、 -C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0116] or R a 、R d and R eAny two atoms to which they are connected together form a 3- to 8-membered cycloalkyl, a 3- to 8-membered heterocyclyl, a 6- to 10-membered aryl, and a 5- to 10-membered heteroaryl; wherein the 3- to 8-membered cycloalkyl, the 3- to 8-membered heterocyclyl, the 6- to 10-membered aryl, and the 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0117] W is selected from

[0118] Ring B is selected from 3- to 10-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 5- to 7-membered monoheterocyclyl, 7- to 12-membered spiroheterocyclyl, 6- to 10-membered bridged heterocyclyl, and 6- to 10-membered fused heterocyclyl;

[0119] Each R b are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)p NR be R bf and S(O) p R ba ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NRbc R bd and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0120] R b1 、R b2 、R a1 、R a2 、R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0121] or R b1 With R b2 、R a1 With R a2 、R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group; the 3-7 membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 Ra2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0122] Ring C is selected from 3- to 10-membered cycloalkyl, 3- to 10-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0123] Each R c are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0124] n is selected from 0, 1, 2 or 3;

[0125] m is selected from 0, 1, 2 or 3;

[0126] p is selected from 0, 1 or 2.

[0127] The present disclosure provides a compound represented by formula (IA) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0128] in,

[0129] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0130] x 2 Selected from CR x2 、N、C(=O)、C(=CR x2 ), where R x2 Selected from H, halogen, hydroxy, amino, cyano, C 2-6Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0131] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxyl, -NR b1 Rb2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0132] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0133] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0134] x 6 Selected from CR x6 、N、C(=O)、C(=CR x6 ), where R x6 Selected from H, halogen, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0135] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0136] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p 、C(=O)、C(=CR x8 ), where R x8 is the same or different at each occurrence and is independently selected from H, halogen, hydroxy, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be Rbf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0137] or two R's attached to the same carbon x8 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl or 3 to 8-membered heterocyclic group is optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) pNR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0138] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 、C(=CR x8 ), where R x9 is the same or different at each occurrence and is independently selected from H, halogen, hydroxy, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2, nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0139] or two R's attached to the same carbon x9 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl and 3 to 8-membered heterocyclic group are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0140] or R x8 With R x9 and the atoms to which it is connected together form a 3 to 7-membered ring; the 3 to 7-membered ring is optionally selected from halogen, C 1- 6 alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 Ra2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0141] is a single bond or a double bond;

[0142] R a 、R d and R e are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0143] or R a 、R d and R e Any two atoms connected thereto together form a 3- to 8-membered cycloalkyl, a 3- to 8-membered heterocyclyl, a 6- to 10-membered aryl, and a 5- to 10-membered heteroaryl; wherein the 3- to 8-membered cycloalkyl, the 3- to 8-membered heterocyclyl, the 6- to 10-membered aryl, and the 5- to 10-membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0144] W is selected from

[0145] Ring B is selected from 3- to 10-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 5- to 7-membered monoheterocyclyl, 7- to 12-membered spiroheterocyclyl, 6- to 10-membered bridged heterocyclyl, and 6- to 10-membered fused heterocyclyl;

[0146] Each R b are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O) p NR be R bf 、S(O) p R ba ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0147] R b1 、R b2 、R a1 、R a2 、R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C1-6 The alkyl group is substituted by one or more substituents;

[0148] or R b1 With R b2 、R a1 With R a2 、R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group; the 3-7 membered heterocyclic group is optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2- 6 alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0149] Ring C is selected from 3- to 10-membered cycloalkyl, 3- to 10-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0150] Each R c are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1- 6-alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0151] n is selected from 0, 1, 2 or 3;

[0152] m is selected from 0, 1, 2 or 3;

[0153] p is selected from 0, 1 or 2.

[0154] The present disclosure provides a compound represented by formula (IA) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0155] in,

[0156] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0157] x 2 Selected from CR x2 、N、C(=O)、C(=CR x2 ), where R x2 Selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0158] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0159] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0160] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0161] x 6 Selected from CR x6 、N、C(=O)、C(=CR x6 ), where R x6 Selected from H, halogen, hydroxy, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2- 6-alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0162] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxyl, -NR b1 R b2 、C 1-4 Alkyl, -OC 1-4 alkyl;

[0163] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p 、C(=O)、C(=CR x8 ), where R x8 is the same or different at each occurrence and is independently selected from H, halogen, hydroxy, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0164] or two R's attached to the same carbon x8 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl or 3 to 8-membered heterocyclic group is optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0165] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 、C(=CR x8 ), where R x9 is the same or different at each occurrence and is independently selected from H, halogen, hydroxy, -NR b1 R b2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、-C(O)OR bb and -C(O)NR bc R bd ; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0166] or two R's attached to the same carbon x9 Together form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl and 3 to 8-membered heterocyclic group are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0167] or R x8 With R x9 and the atoms to which it is connected together form a 3 to 7-membered ring; the 3 to 7-membered ring is optionally selected from halogen, C 1-6 alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0168] is a single bond or a double bond;

[0169] R a 、R d and R e are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0170] or R a 、R d and R e Any two atoms connected thereto together form a 3- to 8-membered cycloalkyl, a 3- to 8-membered heterocyclyl, a 6- to 10-membered aryl, and a 5- to 10-membered heteroaryl; wherein the 3- to 8-membered cycloalkyl, the 3- to 8-membered heterocyclyl, the 6- to 10-membered aryl, and the 5- to 10-membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0171] W is selected from

[0172] Ring B is selected from 3- to 10-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 5- to 7-membered monoheterocyclyl, 7- to 12-membered spiroheterocyclyl, 6- to 10-membered bridged heterocyclyl, and 6- to 10-membered fused heterocyclyl;

[0173] Each R b are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -NR b1 R b2 、-C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf ; wherein, the C 1- 6 alkyl, C2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2- 6-alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0174] R b1 、R b2 、R a1 、R a2 、R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0175] or R b1 With R b2 、R a1 With R a2 、R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group; the 3-7 membered heterocyclic group is optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2- 6 alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0176] Ring C is selected from 3- to 10-membered cycloalkyl, 3- to 10-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl;

[0177] Each R c are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, -NR b1 R b2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc Rbd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are substituted with one or more substituents selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy and hydroxy C 1-6 The alkyl group is substituted by one or more substituents;

[0178] n is selected from 0, 1, 2 or 3;

[0179] m is selected from 0, 1, 2 or 3;

[0180] p is selected from 0, 1 or 2.

[0181] In some embodiments of the present disclosure, the compound represented by formula (IA) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R d and R e The atoms to which it is attached together form a 3- to 8-membered cycloalkyl group or a 3- to 8-membered heterocyclic group, preferably a 3- to 6-membered cycloalkyl group or a 3- to 6-membered heterocyclic group, more preferably a cyclopropyl group.

[0182] In some embodiments of the present disclosure, the compound represented by formula (IA) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R d and R e The atoms to which it is attached together form an oxetane group.

[0183] In some embodiments of the present disclosure, the compound represented by formula (IA) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, is a compound represented by formula (I) and its pharmaceutically acceptable salt, or its stereoisomer,

[0184] in, Ring B, Ring C, R b 、R a 、R c ,m,n,W,x 1 to x 9 As defined in any one of Formula (IA).

[0185] The present disclosure provides a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0186] in,

[0187] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0188] x 2 Selected from CR x2 , N, C(=O), where R x2 Selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 alkyl, amino C 1-6 Alkyl, halogenated C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, halo C 1-6 Alkyl, halogenated C 1-6 Alkoxy, -OC 1-6 Alkyl, hydroxy C 1-6 Alkyl, -NHC1-6 Alkyl, -N(C 1-6 Alkyl)2;

[0189] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0190] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0191] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0192] x 6 Selected from CR x6 , N, C(=O), where R x6 Selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1- 6 alkyl, amino C 1-6 Alkyl, halogenated C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, halo C 1-6 Alkyl, halogenated C 1-6 Alkoxy, -OC 1-6 Alkyl, hydroxy C 1-6 Alkyl, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2;

[0193] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0194] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p , C(=O), where R x8 are the same or different at each occurrence and are independently selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, amino C 1-6 Alkyl, halogenated C 2- 6-alkenyl, halogenated C 2-6 Alkynyl, halo C 1-6 Alkyl, halogenated C 1-6 Alkoxy, -OC 1-6 Alkyl, hydroxy C 1-6 Alkyl, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2;

[0195] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 , where R x9 are the same or different at each occurrence and are independently selected from H, halogen, hydroxy, amino, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, amino C 1-6 Alkyl, halogenated C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, halo C 1-6 Alkyl, halogenated C 1-6 Alkoxy, -OC 1-6 Alkyl, hydroxy C 1-6 Alkyl, -NHC 1-6 Alkyl, -N(C 1-6 Alkyl)2; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0196] or R x8 With R x9 Together with the atoms to which it is attached, it forms a 3-7 membered ring;

[0197] is a single bond or a double bond;

[0198] R a Selected from hydrogen, halogen, C 1-6 Alkyl, cyano, amino, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2- 6 alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkoxy C 1- 6-alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ;

[0199] W is selected from

[0200] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0201] Each R b are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, amino, hydroxyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, halo-C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf ;;

[0202] R ba 、R bb 、R bc 、R bd 、R be 、R bfare the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0203] Ring C is selected from 5-6 membered heteroaryl;

[0204] Each R c are the same or different and are each independently selected from hydrogen, halogen, C 1-6 Alkyl, cyano, amino, hydroxyl, C 2-6 Alkenyl, C 2- 6-Alkynyl, halo-C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ;

[0205] n is selected from 0, 1, 2 or 3;

[0206] m is selected from 0, 1, 2 or 3;

[0207] p is selected from 0, 1 or 2;

[0208] and,

[0209] When W is selected And R a When selected from -CH3, cyano, -CH2F, -CONH2; structural unit Not for R x9 Selected from H, C 1-4 Alkyl, R x9a Selected from H, -CH3, F, Cl.

[0210] The present disclosure provides a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0211] in,

[0212] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0213] x 2 Selected from CR x2 , N, C(=O), where R x2 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0214] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0215] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0216] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0217] x 6Selected from CR x6 , N, C(=O), where R x6 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0218] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0219] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p , C(=O), where R x8 are the same or different at each occurrence and are independently selected from H, C≡CH, CN, halogen, C 1-4 Alkyl; or two R attached to the same carbon x8 Together they form C 3-6 Cycloalkyl;

[0220] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 , where R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-4 Alkyl; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0221] or R x8 With R x9 Together with the atoms to which it is attached, it forms a 3-7 membered ring;

[0222] is a single bond or a double bond;

[0223] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4Alkyl, C 1-4 alkyl halide;

[0224] W is selected from

[0225] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0226] Each R b are the same or different and are each independently selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf , where R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0227] Ring C is selected from 5-6 membered heteroaryl;

[0228] Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0229] n is selected from 0, 1, 2 or 3;

[0230] m is selected from 0, 1, 2 or 3;

[0231] p is selected from 0, 1 or 2;

[0232] and,

[0233] When W is selected When; structural unit Not for R x9 Selected from H, C 1-4 alkyl.

[0234] The present disclosure provides a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof,

[0235] in,

[0236] x 1 Selected from C, N;

[0237] x 2 Selected from CR x2 , N, C(=O), where R x2 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0238] x 3 Selected from C, N;

[0239] x 4 Selected from C, N;

[0240] x 5 Selected from C, N;

[0241] x 6 Selected from CR x6 , N, C(=O), where R x6 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0242] x 7 Selected from C, N;

[0243] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O)2、C(=O), where R x8Selected from H, C≡CH, CN, halogen, C 1- 4 alkyl; or two R attached to the same carbon x8 Together they form C 3-6 Cycloalkyl;

[0244] x 9 Selected from CR x9 、N、O、NR x9 , CR x9 R x9 , where R x9 Selected from H halogen, C 1-4 Alkyl; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0245] or R x8 With R x9 The atoms to which they are connected together form a 3-7 membered ring;

[0246] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 alkyl halide;

[0247] W is selected from

[0248] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0249] R b Selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Haloalkoxy, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf , where R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1- 4 alkyl or R bc With R bd 、R be With R bfTogether with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0250] Ring C is selected from 5-6 membered heteroaryl;

[0251] R c Selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0252] n is selected from 0, 1, 2 or 3;

[0253] m is selected from 0, 1, 2 or 3;

[0254] and,

[0255] Structural unit Not for

[0256] In some embodiments of the present disclosure, the structural unit for in x 2 、x 4 、x 6 、x 7 、x 8 、x 9 As defined in any one of Formula (I) or as defined in any one of Formula (IA).

[0257] The present disclosure provides a compound represented by formula (I-1) or formula (I-1A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0258] in: x 2 、x 4 、x 6 、x 7 、x 8 、x 9 、R a 、R b 、R c , Ring B, Ring C, n, m, and p are as defined in any one of Formula (IA) or any one of Formula (I).

[0259] In some embodiments of the present disclosure, the compound represented by Formula (I-1) or Formula (I-1A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein:

[0260] x 2 Selected from CR x2 , N, where R x2 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0261] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0262] x 6 Selected from CR x6 , N, where R x6 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0263] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0264] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p , C(=O), where R x8 are the same or different at each occurrence and are independently selected from H, C≡CH, CN, halogen, C 1-4 Alkyl; or two R attached to the same carbon x8 Together they form C 3-6Cycloalkyl;

[0265] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 , where R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-4 Alkyl; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0266] or R x8 With R x9 The atoms to which they are connected together form a 3-7 membered ring;

[0267] is a single bond or a double bond;

[0268] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 alkyl halide;

[0269] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0270] Each R b are the same or different and are each independently selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf ;

[0271] R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C1-6 Alkyl, amino C 1- 6 alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0272] Ring C is selected from 5-6 membered heteroaryl;

[0273] Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0274] n is selected from 0, 1, 2 or 3;

[0275] m is selected from 0, 1, 2 or 3;

[0276] p is selected from 0, 1 or 2.

[0277] In some embodiments of the present disclosure, the structural unit for Wherein ring D and ring E are both aromatic rings, x 2 、x 4 、x 5 、x 6 、x 7 、x 8 、x 9 As defined in any one of Formula (I) or as defined in any one of Formula (IA).

[0278] The present disclosure provides a compound represented by formula (I-2) or formula (I-2A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0279] in: x 2 、x 4 、x 5 、x 6 、x 7 、x 8 、x 9 、R a 、R b 、R c , Ring B, Ring C, n, m, and p are as defined in any one of Formula (IA) or any one of Formula (I).

[0280] In some embodiments of the present disclosure, the compound represented by formula (I-2) or formula (I-2A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein:

[0281] x 2 Selected from CR x2 , N, C(=O), where R x2 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0282] x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0283] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0284] x 6 Selected from CR x6 , N, C(=O), where R x6 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0285] x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0286] x 8 Selected from N, O, CR x8, CR x8 R x8 NR x8 、S(O) p , C(=O), where R x8 are the same or different at each occurrence and are independently selected from H, C≡CH, CN, halogen, C 1-4 Alkyl; or two R attached to the same carbon x8 Together they form C 3-6 Cycloalkyl;

[0287] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 , where R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-4 Alkyl; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0288] or R x8 With R x9 Together with the atoms to which it is attached, it forms a 3-7 membered ring;

[0289] is a single bond or a double bond;

[0290] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 alkyl halide;

[0291] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0292] Each R b are the same or different and are each independently selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR beR bf , where R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0293] Ring C is selected from 5-6 membered heteroaryl;

[0294] Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0295] n is selected from 0, 1, 2 or 3;

[0296] m is selected from 0, 1, 2 or 3;

[0297] p is selected from 0, 1 or 2; provided that ring D and ring E are both aromatic rings; x 2 and x 6 Not CH at the same time, and Not for

[0298] In some embodiments of the present disclosure, the structural unit R x2 、R x6 、R x8 As defined in any one of Formulas (IA) or any one of Formulas (I).

[0299] In some embodiments of the present disclosure, the structural unit Selected from x 1 、x 2 、x 5 、x 7 、x 8 、x 9 As defined in any one of Formulas (IA) or any one of Formulas (I).

[0300] The present disclosure provides a compound represented by Formula (I-3), Formula (I-3A), Formula (I-3') or Formula (I-3'A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0301] in: x 1 、x 2 、x 5 、x 7 、x 8 、x 9 、R a 、R b 、R c , Ring B, Ring C, n, m, and p are as defined in any one of Formula (IA) or any one of Formula (I).

[0302] In some embodiments of the present disclosure, the compound represented by Formula (I-3), Formula (I-3A), Formula (I-3') or Formula (I-3'A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein:

[0303] x 1 Selected from CR x1 , N, where R x1 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0304] x 2 Selected from CR x2 , N, where R x2 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0305] x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0306] x 7 Selected from C, CRx7 , N, where R x7 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0307] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p , C(=O), where R x8 are the same or different at each occurrence and are independently selected from H, C≡CH, CN, halogen, C 1-4 Alkyl; or two R attached to the same carbon x8 Together they form C 3-6 Cycloalkyl;

[0308] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 , where R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-4 Alkyl; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0309] or R x8 With R x9 The atoms to which they are connected together form a 3-7 membered ring;

[0310] is a single bond or a double bond;

[0311] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 alkyl halide;

[0312] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0313] Each R b are the same or different and are each independently selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf , where R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0314] Ring C is selected from 5-6 membered heteroaryl;

[0315] Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0316] n is selected from 0, 1, 2 or 3;

[0317] m is selected from 0, 1, 2 or 3;

[0318] p is selected from 0, 1 or 2.

[0319] In some embodiments of the present disclosure, the structural unit Selected from in x 1 、x 3 、x 6 、x 7 、x 8 、x 9 As defined in any one of Formulas (IA) or any one of Formulas (I).

[0320] The present disclosure provides a compound represented by Formula (I-4), Formula (I-4A), (I-4') or Formula (I-4'A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0321] in: x 1 、x 3 、x 6 、x 7 、x 8 、x 9 、R a 、R b 、R c , Ring B, Ring C, n, m, and p are as defined in any one of Formula (IA) or any one of Formula (I).

[0322] In some embodiments of the present disclosure, the compound represented by Formula (I-4), Formula (I-4A), (I-4') or Formula (I-4'A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein:

[0323] x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0324] x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0325] x 6 Selected from CR x6 , N, C(=O), where R x6 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0326] x 7Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0327] x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p , C(=O), where R x8 are the same or different at each occurrence and are independently selected from H, C≡CH, CN, halogen, C 1-4 Alkyl; or two R attached to the same carbon x8 Together they form C 3-6 Cycloalkyl;

[0328] x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 , where R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-4 Alkyl; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0329] or R x8 With R x9 The atoms to which they are connected together form a 3-7 membered ring;

[0330] is a single bond or a double bond;

[0331] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 alkyl halide;

[0332] W is selected from

[0333] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0334] Each Rb are the same or different and are each independently selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf , where R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0335] Ring C is selected from 5-6 membered heteroaryl;

[0336] Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0337] n is selected from 0, 1, 2 or 3;

[0338] m is selected from 0, 1, 2 or 3;

[0339] p is selected from 0, 1 or 2.

[0340] In some embodiments of the present disclosure, the structural unit Selected from in x 2 、x 6 、x 7 、x 8 、x 9 As defined in any one of Formulas (IA) or any one of Formulas (I).

[0341] In some embodiments of the present disclosure, the compound represented by formula (I) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, is a compound represented by formula (I-5) or formula (I-5A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative:

[0342] in: x 2 、x 6 、x 7 、x 8 、x 9 、R a 、R b 、R c , Ring B, Ring C, n, m, and p are as defined in any one of Formula (IA) or any one of Formula (I).

[0343] In some embodiments of the present disclosure, the compound represented by formula (I-5) or formula (I-5A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein:

[0344] x 2 Selected from CR x2 , N, C(=O), where R x2 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0345] x 6 Selected from CR x6 , N, C(=O), where R x6 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1- 4-alkyl, -N(C 1-4 Alkyl)2;

[0346] x 7 Selected from CR x7 , N, where R x7 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0347] x 8 Selected from O, CR x8 R x8 NR x8 、S(O) p , C(=O), where R x8 are the same or different at each occurrence and are independently selected from H, C≡CH, CN, halogen, C 1-4 Alkyl; or two R attached to the same carbon x8 Together they form C 3-6 Cycloalkyl;

[0348] x 9 Selected from O, NR x9 、S(O) p , CR x9 R x9 , where R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-4 Alkyl; or two R attached to the same carbon x9 Together they form C 3-6 Cycloalkyl;

[0349] or R x8 With R x9 Together with the atoms to which it is attached, it forms a 3-7 membered ring;

[0350] is a single bond or a double bond;

[0351] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 alkyl halide;

[0352] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0353] Each R b are the same or different and are each independently selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd、S(O)2NR be R bf , where R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0354] Ring C is selected from 5-6 membered heteroaryl;

[0355] Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0356] n is selected from 0, 1, 2 or 3;

[0357] m is selected from 0, 1, 2 or 3;

[0358] p is selected from 0, 1 or 2.

[0359] In some embodiments of the present disclosure, the structural unit for R x2 、R x6 、R x9 As defined in any one of Formulas (IA) or any one of Formulas (I).

[0360] In some embodiments of the present disclosure, the structural unit for x 2 、x 6 、x 8 、x 9 As defined in any one of Formulas (IA) or any one of Formulas (I).

[0361] The present disclosure provides a compound represented by formula (I-6) or formula (I-6A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0362] in: x 2 、x 6 、x 8 、x 9 、R a 、R b 、R c , Ring B, Ring C, n, m, and p are as defined in any one of Formula (IA) or any one of Formula (I).

[0363] In some embodiments of the present disclosure, the compound represented by formula (I-6) or formula (I-6A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: x 2 Selected from CR x2 , N, where R x2 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0364] x 6 Selected from CR x6 , N, where R x6 Selected from H, halogen, hydroxy, amino, C 1-4 Alkyl, -OC 1-4 Alkyl, -NHC 1-4 Alkyl, -N(C 1-4 Alkyl)2;

[0365] x 8 Selected from N, CR x8 , where R x8 Selected from H, C≡CH, CN, halogen, C 1-4 alkyl;

[0366] x 9 Selected from O, S;

[0367] or R x8 With R x9 The atoms to which they are connected together form a 3-7 membered ring;

[0368] is a single bond or a double bond;

[0369] R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 alkyl halide;

[0370] Ring B is selected from a 5-7 membered monoheterocyclic group, a 7-12 membered spiroheterocyclic group, a 6-10 membered bridged heterocyclic group, and a 6-10 membered fused heterocyclic group;

[0371] Each R b are the same or different and are each independently selected from hydrogen, hydroxy, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkyl, C 1-6 Halogenated alkoxy, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O)2NR be R bf , where R ba 、R bb 、R bc 、R bd 、R be 、R bf Any independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Halogenated alkyl, hydroxy C 1-6 Alkyl, amino C 1-6 Alkyl or R bc With R bd 、R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group;

[0372] Ring C is selected from 5-6 membered heteroaryl;

[0373] Each R c are the same or different and are each independently selected from hydrogen, halogen, hydroxyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl and C 1-6 haloalkoxy;

[0374] n is selected from 0, 1, 2 or 3;

[0375] m is selected from 0, 1, 2 or 3;

[0376] p is selected from 0, 1 or 2.

[0377] In some embodiments of the present disclosure, in the formula containing ring C, ring C is a 5-membered heteroaryl group, preferably selected from

[0378] In some embodiments of the present disclosure, the above-mentioned Rc In the formula, each R c The same or different, and each independently is C 1-6 preferably, R c Selected from -CHF2.

[0379] In some embodiments of the present disclosure, the above-mentioned ring-containing C and R c In the formula, wherein ring C is a 5-membered heteroaryl group, each R c The same or different, and each independently is C 1-6 Preferably, ring C is R c Selected from -CHF2.

[0380] In some embodiments of the present disclosure, the above-mentioned ring-containing C and R c In the formula, Selected from

[0381] In some embodiments of the present disclosure, the compound represented by formula (IA) or formula (I) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, is a compound represented by formula (II) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative:

[0382] in: x 1 、x 2 、x 3 、x 4 、x 5 、x 6 、x 7 、x 8 、x 9 , Ring B, R b 、R a , n is as defined in any one of formula (I) or any one of formula (IA).

[0383] In some embodiments of the present disclosure, the above-mentioned R a In the formula, R a is selected from -CH3, -CH2F, -CN, -CH2=CHF; preferably, R a Selected from -CH3, -CH2F, -CN.

[0384] In some embodiments of the present disclosure, the above-mentioned R a In the formula, R a Selected from -CHF2, -CHF3.

[0385] In some embodiments of the present disclosure, the above-mentioned R a In the formula, R a Selected from -CD3.

[0386] In some embodiments of the present disclosure, the above-mentioned R b In the formula, each R b are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ; R ba 、R bc 、R bd As defined in any one of Formula (IA) or any one of Formula (I); preferably, each R b are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)NR bc R bd ; R ba 、R bc 、R bd As defined in any one of Formulas (IA) or any one of Formulas (I).

[0387] In some embodiments of the present disclosure, in the above formula containing ring B, ring B is selected from

[0388] In some embodiments of the present disclosure, Ring B is selected from a 6-membered heterocyclyl.

[0389] In some embodiments of the present disclosure, Ring B is selected from

[0390] In some embodiments of the present disclosure, Ring B is selected from

[0391] In some embodiments of the present disclosure, Ring B is selected from

[0392] In some embodiments of the present disclosure, the above-mentioned R b In the formula, R b Selected from

[0393] In some embodiments of the present disclosure, wherein, Selected from

[0394] In some embodiments of the present disclosure, wherein, Selected from

[0395] In some embodiments of the present disclosure, wherein, Selected from

[0396] In some embodiments of the present disclosure, wherein, Selected from

[0397] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b Selected from hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba ; R ba As defined in any one of formula (IA) or any one of formula (I); preferably, Selected from R b Selected from hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba ; R ba Selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 alkyl.

[0398] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl; R ba 、R bb 、R bc 、R bd As defined in claims 1 to 11; preferably, Selected from R b Selected from hydrogen, C1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl; R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl.

[0399] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from

[0400] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) or any one of formula (I); preferably, Selected from

[0401] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd, optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba ; R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in claims 1 to 11; preferably, Selected from R b Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba ; R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl, C 1-6 Alkoxy, C 2-6 alkenyl, 5 to 6 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 5 to 6 membered heteroaryl are optionally selected from C 1-6 Alkyl, halogen, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1- 6-alkoxy, deuterated C 1-6 Alkoxy, -C(O)OR bb1 、-NR a1 R a2 ; R bb1 、R a1 、R a2 As defined in claims 1 to 11.

[0402] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b1 Selected from hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba , R b2 and R b3 The same or different, and each independently selected from C 1-6 Alkyl, R ba As defined in any one of formula (IA) or any one of formula (I); further preferably, Selected from R b1 Selected from hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba , R b2 and R b3 Same, and all selected from C 1-6 Alkyl, R ba As defined in any one of formula (IA) or any one of formula (I); further preferably, Selected from R b1 Selected from hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba , R ba As defined in any one of formula (IA) or any one of formula (I); most preferably, Selected from R b1 Selected from hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba , R ba Selected from hydrogen, C 1-6 alkyl.

[0403] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b1 、R b2 、R b3 are the same or different and are each independently selected from R b , R b As defined in any one of formula (IA) or any one of formula (I); preferably, Selected from R b1 Selected from hydrogen, C 1-6Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 The same or different, and each independently selected from C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) or any one of formula (I); further preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 Same, and all selected from C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) or any one of formula (I); most preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd As defined in any one of Formulas (IA) or any one of Formulas (I).

[0404] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd, optional C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl, R b2 and R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) or any one of formula (I); further preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl, R b2 and R b3 Same, and all selected from C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) or any one of formula (I); further preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl, R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) or any one of formula (I); most preferably, Selected from R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NRbc R bd , optional C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl, R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl.

[0405] In some embodiments of the present disclosure, the above-mentioned ring B and R b In the formula, Selected from R b1 、R b2 、R b3 are the same or different and are each independently selected from R b , R b As defined in claims 1 to 9; preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R b2 and R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in claims 1 to 9; further preferably, Selected from R b1 Selected from hydrogen, C 1-6Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R b2 and R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in claims 1 to 9; further preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in claims 1 to 9; most preferably, Selected from R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc Rbd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R ba 、R bb 、R bc 、R bd 、R be 、R bf are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl, C 1-6 Alkoxy, C 2-6 alkenyl, 5 to 6 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 5 to 6 membered heteroaryl are optionally selected from C 1-6 Alkyl, halogen, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C(O)OR bb1 、-NR a1 R a2 ; R bb1 、R a1 、R a2 As defined in claims 1 to 9.

[0406] In some embodiments of the present disclosure, the compound represented by Formula (IA), Formula (I) or Formula (II) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, is a compound represented by Formula (Ia) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative:

[0407] in: x 1 、x 2 、x 3 、x 4 、x 5 、x 6 、x 7 、x 8 、x 9 As defined in any one of Formula (IA) and any one of Formula (I).

[0408] In some embodiments of the present disclosure, the above-mentioned structural unit In the formula, the structural unit Selected from where R x2 、R x6 、R x8 、R x9 As defined in any one of formula (IA) and any one of formula (I); preferably, the structural unit Selected from More preferably, the structural unit Selected from More preferably, the structural unit Selected from

[0409] In some embodiments of the present disclosure, the above-mentioned structural unit In the formula, the structural unit Selected from Preferably, the structural unit Selected from

[0410] In some embodiments of the present disclosure, the structural unit Selected from

[0411] In some embodiments of the present disclosure, the structural unit Selected from Ring K is an optionally substituted 3-7 membered ring, R x6 、R x8 As defined in any one of Formula (IA) and any one of Formula (I).

[0412] In some embodiments of the present disclosure, Ring K is an optionally substituted 3-7 membered ring.

[0413] In some embodiments of the present disclosure, ring K is a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heterocyclyl or the 5- to 6-membered heteroaryl is optionally selected from deuterium, halogen, C1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd and hydroxy C 1-6 The alkyl group is substituted by one or more substituents; R a1 、R a2 、R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in any one of Formula (IA) and any one of Formula (I).

[0414] In some embodiments of the present disclosure, ring K is

[0415] In some embodiments of the present disclosure, the structural unit Selected from Ring J is an optionally substituted 3-7 membered ring, R x2 、R x6 、R x8 As defined in any one of Formula (IA) and any one of Formula (I).

[0416] In some embodiments of the present disclosure, the structural unit Selected from Ring J is an optionally substituted 5- to 6-membered heterocyclic group or a 5- to 6-membered heteroaryl group, R x8 As defined in any one of Formula (IA) and any one of Formula (I).

[0417] In some embodiments of the present disclosure, the structural unit Selected from Ring J is an optionally substituted 6-membered nitrogen-containing heteroaryl group, R x8 As defined in any one of Formula (IA) and any one of Formula (I).

[0418] In some embodiments of the present disclosure, the structural unit Selected from

[0419] In some embodiments of the present disclosure, Ring J is a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl, wherein the 5- to 6-membered heterocyclyl or the 5- to 6-membered heteroaryl is optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, - C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd and hydroxy C 1-6 The alkyl group is substituted by one or more substituents; R a1 、R a2 、R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in any one of Formula (IA) and any one of Formula (I).

[0420] In some embodiments of the present disclosure, Ring J is

[0421] In some embodiments of the present disclosure, the structural unit Selected from

[0422] In some embodiments of the present disclosure, the above-mentioned structural unit In the formula, the structural unit Selected from where R x2 、R x6 、R x8 、R x9As defined in any one of formula (IA) and any one of formula (I); preferably, the structural unit Selected from

[0423] In some embodiments of the present disclosure, the above-mentioned structural unit In the formula, the structural unit Selected from

[0424] In some embodiments of the present disclosure, the above-mentioned structural unit In the formula, the structural unit Selected from

[0425] In some embodiments of the present disclosure, the structural unit for

[0426] In some embodiments of the present disclosure, the structural unit Selected from Among them, Ring J 1 、Huan J 2 、Huan J 3 、Huan J 4 、Huan J 5 、Huan J 6 、Ring K 1 are the same or different and are each independently an optionally substituted 3-7 membered ring, R x2 、R x6 、R x8 As defined in any one of the aspects of this disclosure.

[0427] In some embodiments of the present disclosure, the structural unit Selected from Among them, Ring K 2 is an optionally substituted 3-7 membered ring, R x2 、R x6 、R x8 As defined in any one of the aspects of this disclosure.

[0428] In some embodiments of the present disclosure, ring J 1 、Huan J 2 、Huan J 3 、Huan J 4 、Huan J 5 、Huan J 6 、Ring K 1The same or different, and each independently is a 5- to 6-membered heterocyclic group or a 5- to 6-membered heteroaryl group, wherein the 5- to 6-membered heterocyclic group or the 5- to 6-membered heteroaryl group is optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd and hydroxy C 1-6 The alkyl group is substituted by one or more substituents; R a1 、R a2 、R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in any one of Formula (IA) and any one of Formula (I).

[0429] In some embodiments of the present disclosure, the structural unit Selected from

[0430] In some embodiments of the present disclosure, the structural unit Selected from

[0431] In some embodiments of the present disclosure, the compound represented by formula (IA) or formula (I) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, is a compound represented by formula (II-1A) or formula (II-2A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0432] in:

[0433] R b1 、R b2 、R b3 are the same or different and are each independently selected from R b ;

[0434] R b 、R a 、R x2 、R x6 、R x8 、R x9 As defined in any one of the aspects of this disclosure.

[0435] In some embodiments of the present disclosure, the compound represented by formula (II-1A), formula (II-2A) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: R b1 、R b2 、R b3 are the same or different and are each independently selected from R b , R b As defined in any one of formula (IA) and any one of formula (I); preferably, R b1 、R b2 、R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) and any one of formula (I); further preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 The same or different, and each independently selected from C 1-6 Alkyl, R ba 、R bb 、Rbc 、R bd As defined in any one of formula (IA) and any one of formula (I); further preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 Same, and all selected from C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) and any one of formula (I); further preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 are all selected from methyl, R ba 、R bb 、 R bc 、R bd As defined in any one of formula (IA), any one of formula (I); most preferably, R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 are all selected from methyl, R ba 、R bb 、R bc 、R bd If the same or different, and each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 alkyl;

[0436] R a 、Rx2 、R x6 、R x8 、R x9 As defined in any one of Formula (IA) and any one of Formula (I).

[0437] In some embodiments of the present disclosure, the compound represented by formula (II-1A), formula (II-2A) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: R b1 、R b2 、R b3 are the same or different and are each independently selected from R b , R b As defined in any one of formula (IA) and any one of formula (I); preferably, R b1 、R b2 、R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) and any one of formula (I); further preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 The same or different, and each independently selected from C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) and any one of formula (I); further preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 Same, and all selected from C 1-6 Alkyl, R ba 、Rbb 、R bc 、R bd As defined in any one of formula (IA), any one of formula (I); most preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 are all selected from methyl, R ba 、R bb 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I); R a 、R x2 、R x6 、R x8 、R x9 As defined in any one of Formula (IA) and any one of Formula (I).

[0438] In some embodiments of the present disclosure, the compound represented by formula (II-1A), formula (II-2A) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: R b1 、R b2 、R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba ; R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in any one of Formula (IA) and any one of Formula (I).

[0439] In some embodiments of the present disclosure, the compound represented by formula (II-1A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: R b2 、R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl; preferably, R b2 、R b3 are all selected from hydrogen.

[0440] In some embodiments of the present disclosure, the compound represented by formula (II-2A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: R b2 、R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl; preferably, R b2 、R b3 are the same or different and are each independently selected from hydrogen or methyl.

[0441] In some embodiments of the present disclosure, the compound represented by formula (IA) or formula (I) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, is a compound represented by formula (II-1B) or formula (II-2B) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0442] in:

[0443] R b1 Selected from R b ; R b 、R a 、R x2 、R x6 、R x8 、R x9 As defined in any one of the aspects of this disclosure.

[0444] In some embodiments of the present disclosure, the compound represented by Formula (IA) or Formula (I) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, is a compound represented by Formula (II-1C) or Formula (II-2C) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0445] in:

[0446] R b1 Selected from R b ; R b 、R a 、R x2 、R x6 、R x8 、R x9 As defined in any one of the aspects of this disclosure.

[0447] In some embodiments of the present disclosure, the compounds represented by formula (II-1B), formula (II-1C), formula (II-2B), formula (II-2C) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: R b1 Selected from R b , R b As defined in any one of formula (IA) and any one of formula (I); preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA) and any one of formula (I); More preferably, R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd If the same or different, and each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 alkyl;

[0448] R a 、R x2 、R x6 、R x8 、R x9As defined in any one of Formula (IA) and any one of Formula (I).

[0449] In some embodiments of the present disclosure, the compound represented by formula (IA) or formula (I) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, is a compound represented by formula (II-2D), formula (II-2E), or formula (II-2F) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof:

[0450] in:

[0451] is a single bond or a double bond;

[0452] x 4 、x 5 、x 7 、x 9 are the same or different and are each independently selected from N or C; and x 4 、x 5 、x 7 、x 9 The ring where it is located is an aromatic ring;

[0453] R x8 is selected from an optionally substituted 4- to 7-membered heterocyclic group, preferably an optionally substituted 5- to 7-membered heterocyclic group, more preferably an optionally substituted 5- to 7-membered oxygen-containing heterocyclic group; wherein the optionally substituted 5- to 7-membered heterocyclic group is selected from halogen, C 1-6 Alkyl, hydroxyl, -CN, amino, halogenated C 1-6 Alkyl and hydroxy C 1- 6-alkyl;

[0454] R b1 Selected from R b ; R b 、R a As defined in any one of the aspects of this disclosure.

[0455] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II-2D), formula (II-2E), and formula (II-2F) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof are compounds represented by formula (II-2G), formula (II-2H), and formula (II-2J) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof:

[0456] in:

[0457] is a single bond or a double bond;

[0458] x 4 、x 5 、x 7 、x 9 are the same or different and are each independently selected from N or C; and x 4 、x 5 、x 7 、x 9 The ring where it is located is an aromatic ring;

[0459] R x8a Selected from halogen, C 1-6 Alkyl, hydroxyl, -CN, amino, halogenated C 1-6 Alkyl and hydroxy C 1-6 Alkyl; or two R attached to the same carbon atom x8a Together with the carbon atom to which it is connected, it forms a 3- to 6-membered cycloalkyl group; or two adjacent R x8a Together with the attached carbon atom, it forms a 3- to 6-membered cycloalkyl group;

[0460] t is selected from 0, 1, 2, 3 or 4;

[0461] R b1 Selected from R b ; R b 、R a As defined in any one of the aspects of this disclosure.

[0462] In some embodiments of the present disclosure, the compounds represented by formula (IA), formula (I), formula (II-2D), formula (II-2E), formula (II-2F), formula (II-2G), formula (II-2H), formula (II-2J) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof are compounds represented by formula (II-2K), formula (II-2L), formula (II-2M) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof:

[0463] in:

[0464] is a single bond or a double bond;

[0465] x 4 、x 5 、x 7 、x 9 are the same or different and are each independently selected from N or C; and x 4、x 5 、x 7 、x 9 The ring where it is located is an aromatic ring;

[0466] R b1 Selected from R b ; R b 、R a As defined in any one of the aspects of this disclosure.

[0467] In some embodiments of the present disclosure, the compounds represented by formula (II-2D), formula (II-2G), formula (II-2K) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein, is a single bond or a double bond; x 4 、x 5 、x 7 are the same or different and are each independently selected from N or C; x 9 is selected from N or CH; and x 4 、x 5 、x 7 、x 9 The ring where it is located is an aromatic ring;

[0468] R b1 Selected from R b ; R b 、R a As defined in any one of the aspects of this disclosure.

[0469] In some embodiments of the present disclosure, the compounds represented by formula (II-2D), formula (II-2G), and formula (II-2K), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein x 4 、x 5 、x 7 are the same or different and are each independently selected from N or C;

[0470] x 9 selected from N or CH;

[0471] Preferably, x 4 、x 5 、x 7 、x 9 The number of N is 1 or 2.

[0472] In some embodiments of the present disclosure, the compounds represented by formula (II-2D), formula (II-2G), formula (II-2K) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: Selected from

[0473] In some embodiments of the present disclosure, the compounds represented by formula (II-2E), formula (II-2H), formula (II-2L) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: Selected from

[0474] In some embodiments of the present disclosure, the compounds represented by formula (II-2F), formula (II-2J), formula (II-2M) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: Selected from

[0475] In some embodiments of the present disclosure, the compounds represented by formula (II-1B), formula (II-1C), formula (II-2B), formula (II-2C) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: R b1 Selected from R b , R b As defined in any one of formula (IA) and any one of formula (I); preferably, R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I); R a 、R x2 、R x6 、R x8 、R x9 As defined in any one of Formula (IA) and any one of Formula (I).

[0476] In some embodiments of the present disclosure, the compound represented by formula (IA) or formula (I) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, is a compound represented by formula (II-3A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof:

[0477] in:

[0478] is a single bond or a double bond;

[0479] x 4 、x 5 、x 7 、x 8 、x 9 are the same or different and are each independently selected from N or C; and x 4 、x 5 、x 7 、x 8 、x 9 The ring where it is located is an aromatic ring;

[0480] Ring J 7 is selected from 5- to 10-membered heteroaryl or 3- to 8-membered heterocyclyl;

[0481] q is selected from 0, 1 or 2;

[0482] R b1 Selected from R b ; R b 、R a 、R x8 As defined in any one of the aspects of this disclosure.

[0483] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: 4 、x 5 、x 7 、x 8 、x 9 The number of N is 1 or 2.

[0484] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Ring J 7 is selected from 5- to 6-membered heteroaryl or 5- to 6-membered heterocyclic group; more preferably, ring J 7is selected from a 5- to 6-membered nitrogen-containing heteroaryl group or a 5- to 6-membered nitrogen-containing heterocyclic group; further preferably, ring J 7 is selected from 5 to 6 membered nitrogen-containing heteroaryl groups; most preferably, ring J 7 is selected from 5-membered nitrogen-containing heteroaryl groups.

[0485] In some embodiments of the present disclosure, wherein Ring J, Ring J 1 、Huan J 2 、Huan J 3 、Huan J 4 、Huan J 5 、Huan J 6 、Huan J 7 、Ring K 1 、Ring K 2 and Ring K are the same as or different from each other and are each independently a 3-7 membered ring, preferably a 5- to 10-membered heteroaryl group or a 3- to 8-membered heterocyclic group, more preferably a 5- to 10-membered heteroaryl group, further preferably a 5- to 6-membered nitrogen-containing heteroaryl group, and most preferably a 5-membered nitrogen-containing heteroaryl group.

[0486] In some embodiments of the present disclosure, the compounds represented by formula (II-1A), formula (II-1B), formula (II-1C) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba Preferably, R b1 Selected from -S(O)2R ba 、-C(O)R ba 、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd 、R be 、R bf As defined in any one of Formula (IA) and any one of Formula (I).

[0487] In some embodiments of the present disclosure, the compounds represented by formula (II-2A), formula (II-2B), formula (II-2C), formula (II-2D), formula (II-2E), formula (II-2F), formula (II-2G), formula (II-2H), formula (II-2J), and formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein: R b1 Selected from hydrogen.

[0488] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from Rx8 is as defined in any of the schemes in this disclosure.

[0489] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from R x8 As defined in any of the embodiments of the present disclosure; preferably, Selected from R x8 As defined in any embodiment of the present disclosure; more preferably, Selected from R x8 is selected from hydrogen, deuterium, halogen, hydroxy, amino, C optionally substituted by one or more halogen or hydroxy groups 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 An alkyl-substituted 3- to 8-membered heterocyclic group.

[0490] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0491] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0492] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0493] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0494] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0495] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0496] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from R x8 As defined in any of the embodiments of the present disclosure; preferably, Selected from R x8 As defined in any embodiment of the present disclosure; more preferably, Selected from R x8 is selected from hydrogen, deuterium, halogen, hydroxy, amino, C optionally substituted by one or more halogen or hydroxy groups 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 An alkyl-substituted 3- to 8-membered heterocyclic group.

[0497] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from R x8 As defined in any of the embodiments of the present disclosure; preferably, Selected from R x8 As defined in any embodiment of the present disclosure; more preferably, Selected from R x8 is selected from hydrogen, deuterium, halogen, hydroxy, amino, C optionally substituted by one or more halogen or hydroxy groups 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 An alkyl-substituted 3- to 8-membered heterocyclic group.

[0498] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from R x8 As defined in any aspect of the present disclosure.

[0499] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0500] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein: Selected from

[0501] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (II-1A), Formula (II-1B), Formula (II-2A), Formula (II-2B), Formula (II-1C), Formula (II-2C), Formula (II-3A), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R a Selected from -CD3.

[0502] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (II-1A), Formula (II-1B), Formula (II-2A), Formula (II-2B), Formula (II-1C), Formula (II-2C), Formula (II-3A), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R a Selected from hydrogen, cyano, formyl, -CONH2, -CH2OH, -CH2OC 1-4 Alkyl, C 1-4 Alkyl, C 1-4 Halogenated alkyl, halogenated C 2-6 Alkenyl; preferably, R a Selected from -CH3, -CH2F, -CN, -CH2=CHF.

[0503] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (II-1A), Formula (II-1B), Formula (II-2A), Formula (II-2B), Formula (II-1C), Formula (II-2C), Formula (II-3A), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R a Selected from -CH3, -CH2F, -CN.

[0504] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (II-1A), Formula (II-1B), Formula (II-2A), Formula (II-2B), Formula (II-1C), Formula (II-2C), Formula (II-3A), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R a Selected from -CHF2, -CHF3.

[0505] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, -C(O)R ba、-C(O)OR bb 、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd As defined in any one of formula (IA), any one of formula (I); preferably, each R b are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)NR bc R bd ; R ba 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I).

[0506] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b 、R b1 The same or different, and each independently selected from hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba ; R ba As defined in any one of formula (IA), any one of formula (I); preferably, each R b 、R b1 The same or different, and each independently selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba ; R ba Selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 alkyl.

[0507] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b 、R b1 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)OR bb 、-C(O)R ba 、-C(O)NR bc R bd , optional C 1-6 Alkyl-substituted 5- to 6-membered heteroaryl; R ba 、 R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1- 6-alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl.

[0508] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b 、R b1are the same or different and are each independently selected from hydrogen,

[0509] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b 、R b1 The same or different, and each independently selected from

[0510] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b 、R b1 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba ; R ba、R bb 、R bc 、R bd 、R be 、R bf As defined in any one of the aspects of this disclosure.

[0511] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R b2 and R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl; preferably, R b2 and R b3 are the same or different and are each independently selected from hydrogen, methyl, vinyl, and ethynyl.

[0512] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b 、R b1 are the same or different and are each independently selected from methyl, vinyl, ethynyl,

[0513] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b 、R b1 The same or different, and each independently selected from

[0514] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (II-1A), Formula (II-1B), Formula (II-2A), Formula (II-2B), Formula (II-1C), Formula (II-2C), Formula (II-3A), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein each R b are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)NR bc R bd ; R ba 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I).

[0515] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein x 2 Selected from N, CR x2 ; R x2 Selected from H, halogen, C 1-6 Alkyl, preferably H, Cl, F, CH3.

[0516] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x2 Selected from H, halogen, C 1-6 Alkyl, preferably H, Cl, F, CH3.

[0517] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x2 Selected from H, Cl, F, CH3.

[0518] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein x 6 Selected from N, CR x6 ; R x6 Selected from H, halogen, C 1-6 Alkyl, preferably H, Cl, F, CH3.

[0519] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x6 Selected from H, halogen, C 1-6 Alkyl, preferably H, Cl, F, CH3.

[0520] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-4), Formula (I-4A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-2A), and Formula (II-2B), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x6 Selected from H, Cl, F, CH3.

[0521] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein x 9 Selected from N, NR x9 , CR x9 , CR x9 R x9 ; R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-6 Alkyl, preferably H, Cl, F, CH3; or two R attached to the same carbon x9 The atoms connected to it together form C 3-6 Cycloalkyl, wherein C 3-6 The cycloalkyl group is preferably cyclopropane.

[0522] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein x 9 Selected from O.

[0523] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (Ia), Formula (II-1A), Formula (II-1C), and Formula (II-1B), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x9are the same or different at each occurrence and are independently selected from H, halogen, C 1-6 Alkyl, preferably H, Cl, F, CH3, CH(CH3)2.

[0524] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (Ia), Formula (II-1A), Formula (II-1C), and Formula (II-1B), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x9 is the same or different at each occurrence and is independently selected from ethyl, cyclopropyl, -CH2CF3.

[0525] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (Ia), Formula (II-1A), Formula (II-1C), and Formula (II-1B), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x9 is the same or different at each occurrence and is independently

[0526] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1C), and Formula (II-1B), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x9is the same or different at each occurrence and is independently selected from H, Cl, F, CH3.

[0527] In some embodiments of the present disclosure, the above-mentioned x9 In the formula, two R x9 The atoms to which it is attached together form a 3- to 6-membered cycloalkyl group, wherein the 3- to 6-membered cycloalkyl group is preferably cyclopropane.

[0528] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein x 8 Selected from N, NR x8 , CR x8 , CR x8 R x8 ; R x8 are the same or different at each occurrence and are independently selected from H, halogen, amino, C≡CH, CN, C 1-6 alkyl.

[0529] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), and Formula (I-5A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein x 8 Selected from C(=O).

[0530] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), and Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 are the same or different at each occurrence and are independently selected from H, halogen, amino, C≡CH, CN, C 1-6 alkyl.

[0531] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), and Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 The same or different at each occurrence and are each independently selected from methyl, amino, methoxy.

[0532] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), and Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 are the same or different at each occurrence and are each independently selected from deuterium,

[0533] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), and Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 are the same or different at each occurrence and are each independently selected from oxo, Cl, F, ethyl, trifluoromethyl, isopropyl, cyclopropyl,

[0534] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), and Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 are the same or different at each occurrence and are each independently selected from hydrogen, deuterium, oxo, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, -NHC(O)R ba 、-OR f 、-C(O)R ba 、-S(O)2R ba 、-N=S(O)R ba 、-C(O)NR bc R bd , 3 to 8 membered heterocyclic group, 5 to 10 membered heteroaryl group; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, hydroxyl, C 1-6 The alkyl group is substituted by one or more substituents; Rf 、R ba 、R bc 、R bd As defined in any of the embodiments of the present disclosure.

[0535] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), and Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 are the same or different at each occurrence and are independently selected from optionally one or more selected from halogen, C 1-6 Alkyl, hydroxyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 alkyl-substituted 3 to 8 membered heterocyclic group, preferably optionally substituted with one or more selected from halogen, C 1-6 Alkyl, hydroxyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 alkyl-substituted 5- to 6-membered heterocyclic group, more preferably optionally substituted with one or more selected from halogen, C 1-6 Alkyl, hydroxyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 The 5- to 6-membered oxygen-containing heterocyclic group substituted by an alkyl group is further preferably optionally substituted by one or more halogens, C 1-6 Alkyl, hydroxyl, hydroxy C 1-6 Alkyl, halogenated C 1-6 The 5-membered oxygen-containing heterocyclic group substituted by an alkyl group is further preferably optionally substituted by one or more halogens, C 1-6 Alkyl, hydroxyl, hydroxy C 1-6 Alkyl, halogenated C 1-6Alkyl-substituted tetrahydrofuranyl, most preferably tetrahydrofuranyl. In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 is the same or different at each occurrence and is independently selected from hydrogen, deuterium, oxo, halogen, hydroxy, amino, C optionally substituted with one or more halogen or hydroxy groups 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 An alkyl-substituted 3- to 8-membered heterocyclic group.

[0536] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-2A), Formula (II-2C), Formula (II-2B), and Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R f are the same or different at each occurrence and are independently selected from hydrogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 alkyl-substituted 3 to 6 membered cycloalkyl, optionally substituted by one or more halogen, C 1-6 An alkyl-substituted 3- to 6-membered heterocyclic group.

[0537] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (Ia), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 and R x9 The atoms to which it is attached together form a 3-7 membered ring, wherein the 3-7 membered ring is selected from 3-7 membered heterocyclyl, C 3-7 Cycloalkyl, C 3-7 Carbocyclic group, 5-6 membered heteroaryl; wherein preferably, the 5-6 membered heteroaryl is furyl.

[0538] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (Ia), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 and R x9 The atoms to which it is attached together form a pyrazinyl group.

[0539] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (Ia), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 and R x9 The atoms to which it is attached together form a 5-membered nitrogen-containing heteroaryl group.

[0540] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (Ia), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), and Formula (I-6A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R x8 and R x9 The atoms to which it is attached together form a 6-membered nitrogen-containing heteroaryl group.

[0541] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R ba Selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl, C 2-6 alkenyl, 5 to 6 membered heteroaryl; wherein said C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 5 to 6 membered heteroaryl are optionally selected from C 1-6 Alkyl, halogen, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, -C(O)OR bb1 、-NR a1 R a2 ; R bb1 、R a1 、R a2 As defined in any of the schemes in this disclosure.

[0542] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R bc and R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl.

[0543] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-4), Formula (I-4A), Formula (I-4'), Formula (I-4'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R a1 、R a2 、R bb and R bb1 are the same or different and are each independently selected from hydrogen, C 1-6 alkyl.

[0544] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B) and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, methyl, -CD3, isopropyl, tert-butyl, In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R ba Selected from hydrogen, isopropyl, tert-butyl, methoxy, tert-butoxy,

[0545] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R bc 、R bd are the same or different and are each independently selected from hydrogen, methyl, -CD3, isopropyl, tert-butyl,

[0546] In some embodiments of the present disclosure, the compounds represented by Formula (IA), Formula (I), Formula (II), Formula (Ia), Formula (I-1), Formula (I-1A), Formula (I-2), Formula (I-2A), Formula (I-3), Formula (I-3A), Formula (I-3'), Formula (I-3'A), Formula (I-5), Formula (I-5A), Formula (I-6), Formula (I-6A), Formula (II-1A), Formula (II-1B), Formula (II-1C), Formula (II-2C), Formula (II-2A), Formula (II-2B), Formula (II-3A), and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein R be 、R bf are the same or different and are each independently selected from hydrogen, methyl, and isopropyl.

[0547] In some embodiments of the present disclosure, the compound represented by formula (II-1A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF, -CHF2, -CHF3; R x2 Selected from H; R x6 Selected from H; R x9 are the same or different at each occurrence and are each independently selected from methyl, ethyl, isopropyl, cyclopropyl, -CH2CF3; and R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、 -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered heterocyclic group, 3 to 8 membered cycloalkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl; R b2 and R b3 All are selected from H.

[0548] In some embodiments of the present disclosure, the compound represented by formula (II-1A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H, halogen, C 1-6 Alkyl; R x6 Selected from H, halogen, C 1-6 Alkyl; R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-6 alkyl; and R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 Same, and all selected from C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I).

[0549] In some embodiments of the present disclosure, the compound represented by formula (II-1A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x9 are the same or different at each occurrence and are independently selected from H, C 1-6 alkyl; and R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C1- 6 alkyl, R b2 and R b3 are the same or different and are independently selected from H, C 1-6 alkyl.

[0550] In some embodiments of the present disclosure, the compound represented by formula (II-1A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x9 are the same or different at each occurrence and are independently selected from H, C 1-6 alkyl; and R b1 Selected from hydrogen, R b2 and R b3 are the same and are all selected from H or methyl.

[0551] In some embodiments of the present disclosure, the compound represented by formula (II-2A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H, halogen, C 1-6 Alkyl; R x6 Selected from H, halogen, C 1-6 Alkyl; R x8 are the same or different at each occurrence and are independently selected from H, halogen, amino, C≡CH, CN, C 1-6 alkyl; and R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R b2 and R b3 Same, and all selected from C 1-6 Alkyl, R ba 、R bb 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I).

[0552] In some embodiments of the present disclosure, the compound represented by formula (II-2A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x8 are the same or different at each occurrence and are independently selected from H, halogen, amino, C≡CH, CN, C 1-6 alkyl; and R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, R b2 and R b3 are the same or different and are independently selected from H, C 1-6 alkyl.

[0553] In some embodiments of the present disclosure, the compound represented by formula (II-2A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x8 are the same or different at each occurrence and are independently selected from H, amino; and R b1 Selected from hydrogen, R b2 and R b3 are the same and are all selected from H or methyl.

[0554] In some embodiments of the present disclosure, the compound represented by formula (II-1B) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R aSelected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H, halogen, C 1-6 Alkyl; R x6 Selected from H, halogen, C 1-6 Alkyl; R x9 are the same or different at each occurrence and are independently selected from H, halogen, C 1-6 alkyl; and R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I).

[0555] In some embodiments of the present disclosure, the compound represented by formula (II-1B) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x9 are the same or different at each occurrence and are independently selected from H, C 1-6 alkyl; and R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1- 6 alkyl.

[0556] In some embodiments of the present disclosure, the compound represented by formula (II-1B) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R aSelected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x9 are the same or different at each occurrence and are independently selected from H, C 1-6 alkyl; and R b1 Selected from hydrogen,

[0557] In some embodiments of the present disclosure, the compound represented by formula (II-2B) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H, halogen, C 1-6 Alkyl; R x6 Selected from H, halogen, C 1-6 Alkyl; R x8 are the same or different at each occurrence and are independently selected from H, halogen, amino, C≡CH, CN, C 1-6 alkyl; and R b1 Selected from hydrogen, C 1-6 Alkyl, -C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , R ba 、R bb 、R bc 、R bd As defined in any one of Formula (IA) and any one of Formula (I).

[0558] In some embodiments of the present disclosure, the compound represented by formula (II-2B) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x8 are the same or different at each occurrence and are independently selected from H, halogen, amino, C≡CH, CN, C 1-6 alkyl; and R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、- C(O)OR bb、-C(O)NR bc R bd ; R ba 、R bb 、R bc 、R bd are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 alkyl.

[0559] In some embodiments of the present disclosure, the compound represented by formula (II-2B) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CH2F, -CN, -CH2=CHF; R x2 Selected from H; R x6 Selected from H; R x8 are the same or different at each occurrence and are independently selected from H, amino; and R b1 Selected from hydrogen,

[0560] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3, -CN; R b1 selected from hydrogen; Selected from R x8 is selected from hydrogen, deuterium, halogen, hydroxy, amino, C optionally substituted by one or more halogen or hydroxy groups 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 An alkyl-substituted 3- to 8-membered heterocyclic group.

[0561] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3; R b1 selected from hydrogen; Selected from Rx8 is selected from hydrogen, deuterium, halogen, hydroxy, amino, C optionally substituted by one or more halogen or hydroxy groups 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 An alkyl-substituted 3- to 8-membered heterocyclic group.

[0562] In some embodiments of the present disclosure, the compound represented by formula (II-3A) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3; R b1 selected from hydrogen; Selected from R x8 is selected from hydrogen, deuterium, halogen, hydroxy, amino, C optionally substituted by one or more halogen or hydroxy groups 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, C 1-6 Alkoxy C 1-6 Alkyl, optionally substituted by one or more selected from halogen, C 1-6 An alkyl-substituted 3- to 8-membered heterocyclic group.

[0563] In some embodiments of the present disclosure, the compound represented by formula (II-2L) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3; R b1 selected from hydrogen; Selected from

[0564] In some embodiments of the present disclosure, the compound represented by formula (II-2M) and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R a Selected from -CH3; R b1 selected from hydrogen; Selected from

[0565] The present disclosure also provides the following compounds and pharmaceutically acceptable salts thereof, or stereoisomers, or prodrugs thereof, or nitrogen oxides, or solvates, or isotopic derivatives thereof, wherein the compound can be selected from any one of the structures in Table 1 below and pharmaceutically acceptable salts thereof, or stereoisomers, or prodrugs thereof, or nitrogen oxides, or solvates, or isotopic derivatives thereof,

[0566] Table 1.

[0567] The present disclosure also provides the following compounds and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein the compound can be selected from any of the following structures and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof,

[0568] The present disclosure also provides the following compounds and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof, wherein the compound can be selected from any of the following structures and pharmaceutically acceptable salts thereof, or stereoisomers thereof, or prodrugs thereof, or nitrogen oxides thereof, or solvates thereof, or isotopic derivatives thereof,

[0569] The present disclosure also provides a pharmaceutical composition containing (preferably a therapeutically effective amount of) the above-mentioned compound or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof and a pharmaceutically acceptable carrier.

[0570] The present disclosure also provides use of the above-mentioned compound or its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, or the above-mentioned pharmaceutical composition in the preparation of a drug for treating PARG-mediated cancer.

[0571] The present disclosure also provides the above-mentioned compound or its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, or the above-mentioned pharmaceutical composition for use in treating PARG-mediated cancer.

[0572] The present disclosure also provides a method for treating PARG-mediated cancer, which comprises administering to a patient a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, or a pharmaceutical composition thereof.

[0573] Preferably, the cancer described in the present disclosure is selected from ovarian cancer, pancreatic cancer, breast cancer, and prostate cancer.

[0574] Technical Effects

[0575] 1. The binding mode conformation (active conformation) of the disclosed compounds in the PARG protein structure highly overlaps with its lowest energy conformation (low-energy conformation), and the energy difference between the two conformations is small. Therefore, in actual binding to the PARG enzyme, the disclosed compounds will exhibit similar or superior binding activity to that of the compound in Reference Example 1.

[0576] 2. The disclosed compounds have a strong inhibitory effect on PARG kinase.

[0577] Description and Definition

[0578] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered ambiguous or unclear without a specific definition, but should be understood according to its ordinary meaning.

[0579] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0580] The term "pharmaceutically acceptable salt" refers to derivatives of the disclosed compounds prepared with relatively nontoxic acids or bases. These salts can be prepared during compound synthesis, isolation, and purification, or by reacting the purified free form of the compound with a suitable acid or base. When the compound contains relatively acidic functional groups, base addition salts are obtained by reaction with alkali metal or alkaline earth metal hydroxides or organic amines. These salts include cations based on alkali and alkaline earth metals, as well as nontoxic ammonium, quaternary ammonium, and amine cations, and also encompass salts of amino acids. When the compound contains relatively basic functional groups, acid addition salts are obtained by reaction with organic or inorganic acids. Examples include hydrochlorides and formates.

[0581] The term "pharmaceutically acceptable carrier" refers to a medium generally accepted in the art for delivering biologically active agents to animals, particularly mammals, and includes, for example, adjuvants, excipients, or vehicles, such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, fragrances, antibacterial agents, antifungal agents, lubricants, and dispersants, depending on the mode of administration and the nature of the dosage form. Pharmaceutically acceptable carriers are formulated within the purview of those skilled in the art based on a wide range of factors. These include, but are not limited to, the type and nature of the active agent being formulated, the subject to whom the composition containing the agent is to be administered, the intended route of administration of the composition, and the intended therapeutic indication. Pharmaceutically acceptable carriers include both aqueous and non-aqueous media, as well as a variety of solid and semisolid dosage forms. In addition to the active agent, such carriers include a variety of different ingredients and additives, and the inclusion of such additional ingredients in a formulation for various reasons (e.g., to stabilize the active agent, binders, etc.) is well known to those skilled in the art.

[0582] The term "prodrug" refers to certain derivatives of the compounds of the present invention that have little or no pharmacological activity themselves, which have a cleavable group and decompose into the compounds of the present invention through solvent decomposition or under physiological conditions. The types of prodrugs include, but are not limited to, amides, esters, anhydrides, salts, etc. The "ester" refers to a derivative formed with a suitable alcohol when the compound of the present invention contains an acidic group (such as a carboxylic acid); when the compound of the present invention contains a hydroxyl group, it is formed with a suitable acid (including an organic acid or an inorganic acid). The preparation method of prodrugs is well known to those skilled in the art.

[0583] The term "solvate" refers to an association or complex of one or more solvent molecules with a compound of the present disclosure. The term "hydrate" may be used when the solvent is water. The solvent molecules may be present in stoichiometric or non-stoichiometric amounts.

[0584] The term "nitrogen oxide" or "N-oxide" refers to a derivative formed by further oxidation of the nitrogen atom in a nitrogen-containing group. Common N-oxides include N-oxides of tertiary amines or nitrogen atoms in nitrogen-containing heterocycles. Synthesis methods of N-oxides are well known to those skilled in the art and include oxidation of heterocycles and tertiary amines using peroxyacids such as peracetic acid and m-chloroperbenzoic acid, hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxiranes such as dimethyldioxirane.

[0585] The term "effective prophylactic or therapeutic amount" refers to a sufficient amount of a compound of the present disclosure, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof to treat a disorder at a reasonable benefit / risk ratio applicable to any medical treatment and / or prevention. However, it should be understood that the total daily dosage of the compound of Formula I of the present disclosure, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, and the composition thereof, must be determined by the attending physician within the scope of sound medical judgment. For any particular patient, the specific therapeutically effective dosage level must be determined based on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the patient's age, weight, general health, sex, and diet; the administration time, route of administration, and excretion rate of the specific compound employed; the duration of treatment; drugs used in combination with or concurrently with the specific compound employed; and similar factors well known in the medical field.

[0586] The term "optionally" means that it may be substituted or not substituted. Unless otherwise specified, the type and number of substituents can be any on the basis of chemical practicability. For example, the term "optionally substituted with one or more R d "Substituted" means that one or more R d Replaced by R d replace.

[0587] When any variable (such as R d ) appears more than once in a compound's composition or structure, its definition is independent in each instance. For example, Indicates that the cyclopentyl group is surrounded by 3 R d is replaced, and each R d There are independent options.

[0588] When a substituent's bond crosses two atoms in a ring, the substituent may be bonded to any atom in the ring. It means that the substituent R1 can be substituted at any position on the benzene ring.

[0589] When a substituent is listed without specifying the atom through which it is bonded to the compound included in the general chemical formula but not specifically mentioned, the substituent may be bonded through any atom thereof. For example, pyrazole as a substituent means that any carbon atom or nitrogen atom on the pyrazole ring is bonded to the substituted group; when the structure appears , it indicates that the atom is a bonding atom, for example It indicates that the nitrogen atom on the morpholine ring is a bonding atom.

[0590] Unless otherwise specified, "ring" refers to saturated, partially saturated or unsaturated monocycles and polycycles, and "polycycles" include spirocycles, condensed rings or bridged rings. The group derived from the ring by removing hydrogen atoms is called a "cyclic group", which includes a monovalent ring, a divalent ring (commonly referred to as a subring), a trivalent ring, a tetravalent ring, etc., and the specific valence depends on the number of substituents connected to the ring. The description of "cyclic group" in this disclosure no longer specifically distinguishes the valence of the ring. Representative "rings" include substituted or unsubstituted heterocyclic groups, cycloalkyl groups, heterocycloalkyl groups, cycloalkenyl groups, heterocycloalkenyl groups, cycloalkynyl groups, heterocycloalkynyl groups, aryl groups or heteroaryl groups. The term "hetero" refers to substituted or unsubstituted heteroatoms and oxidized forms of heteroatoms, also known as heteroatoms. The heteroatoms are generally selected from N, O, S, and P. Oxidized forms generally include NO, P(O), SO, and S(O)2. The nitrogen atom can be substituted, i.e., NR (R is H or other substituents defined herein). The number of atoms in the ring is generally defined as the number of ring members. For example, "3-6 membered heterocycloalkyl" refers to a ring composed of 3-6 atoms arranged around, each ring optionally containing 1 to 3 heteroatoms and / or heteroatoms, i.e., N, O, S, NO, SO, S(O)2, P(O), or NR, each ring optionally substituted by an R group, where R is a group defined herein.

[0591] Unless otherwise specified, "cycloalkyl" refers to a saturated or unsaturated monocyclic or polycyclic hydrocarbon group. 3-8 Monocyclic alkyl (also known as 3 to 8 membered cycloalkyl), further preferably C 3-7 Monocyclic alkyl (also known as 3 to 7 membered cycloalkyl), more preferably C 3-6 Monocyclic alkyl (also known as 3- to 6-membered cycloalkyl), examples of which include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Unless otherwise specified, the cycloalkyl groups described herein include monocyclic alkyl, spirocyclic alkyl, fused cycloalkyl, and bridged cycloalkyl.

[0592] Unless otherwise specified, "heterocyclyl" refers to a non-aromatic monocyclic or polycyclic ring containing a certain number of heteroatoms and / or heteroatomic groups in the ring, which may be saturated or partially saturated (e.g., containing one, two or more double bonds). The heteroatoms and / or heteroatomic groups are generally selected from N, O, S, P, NO, SO, S(O)2, P(O), and NR, wherein the carbon atoms in the heterocyclic ring are optionally oxoed, i.e., forming -C(O)-. The "heterocyclic group" is preferably a 3-8 membered heterocyclic group, a 3-8 membered monoheterocyclic group, further preferably a 3-7 membered heterocyclic group, a 3-7 membered monoheterocyclic group, more preferably a 5-6 membered heterocyclic group, a 5-6 membered monoheterocyclic group, and examples of these monoheterocyclic groups include, but are not limited to, piperidinyl, piperazinyl, malinyl, tetrahydropyranyl, 1,4-dioxanyl, tetrahydropyrrolyl, tetrahydrofuranyl, [1,2]oxazinyl, isoxazolinyl, oxetanyl, azetidinyl, etc. Polycyclic heterocyclic groups include spiro heterocyclic groups, fused heterocyclic groups, and bridged heterocyclic groups. Unless otherwise specified, the heterocyclic groups described in the present disclosure include monoheterocyclic groups, spiro heterocyclic groups, fused heterocyclic groups, and bridged heterocyclic groups. For example, the range of 3- to 8-membered heterocyclic groups includes 3- to 8-membered spiro heterocyclic groups, 3- to 8-membered fused heterocyclic groups, and 3- to 8-membered bridged heterocyclic groups.

[0593] Unless otherwise specified, the term "spiroheterocyclyl" refers to a polycyclic heterocyclic group in which 5 to 20-membered monocyclic rings share one atom (called a spiro atom), which optionally contains one or more double bonds, wherein the heteroatom is selected from N, O, S, P, P(O), NO, SO, S(O)2, etc. Spiroheterocyclyl is preferably a 5-13-membered spiroheterocyclyl, a 6-12-membered spiroheterocyclyl, a 5-11-membered spiroheterocyclylalkyl, a 7-11-membered spiroheterocyclyl or a 9-11-membered spiroheterocyclyl, such as wait.

[0594] Unless otherwise specified, the term "fused heterocyclic group" refers to a 5- to 20-membered polycyclic heterocyclic group having a pair of adjacent atoms shared between the rings, one or more rings may contain one or more double bonds, wherein the heteroatom is selected from N, O, S, P, P(O), NO, SO, S(O)2, etc. Preferably, it is 6- to 14-membered, more preferably 7- to 10-membered (e.g., 7, 8, 9 or 10-membered), more preferably 7- to 10-membered, and can be divided into bicyclic, tricyclic, tetracyclic and other polycyclic fused heterocyclic groups according to the number of constituent rings, preferably a bicyclic or tricyclic fused heterocyclic group, more preferably a 3-membered / 4-membered, 3-membered / 5-membered, 3-membered / 6-membered, 4-membered / 4-membered, 4-membered / 5-membered, 4-membered / 6-membered, 5-membered / 3-membered, 5-membered / 4-membered, 5-membered / 5-membered, 5-membered / 6-membered, 6-membered / 3-membered, 6-membered / 4-membered, 6-membered / 5-membered, 6-membered / 6-membered, 6-membered / 7-membered, 7-membered / 5-membered or 7-membered / 6-membered bicyclic fused heterocyclic group, such as wait.

[0595] Unless otherwise specified, the term "bridged heterocyclic group" refers to a polycyclic heterocyclic group with 5 to 14 members, wherein any two rings share two atoms that are not directly connected, and which may contain one or more double bonds, wherein the heteroatom group is selected from N, O, S, P, P(O), NO, SO, S(O)2, etc. Preferably, it has 6 to 14 members, and more preferably 7 to 10 members (e.g., 7, 8, 9 or 10 members). According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic and other polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic bridged heterocyclic groups, more preferably bicyclic bridged heterocyclic groups, such as wait.

[0596] Unless otherwise specified, the term "heteroaryl" means a stable monocyclic (monocyclic heteroaryl) or polycyclic aromatic hydrocarbon (polycyclic heteroaryl) containing at least one heteroatom or heteroatom group (selected from N, O, S, P, P(O), NO, SO, S(O)2 or NR). Preferably, it is a 5- to 10-membered heteroaryl; more preferably, it is a 5- or 6-membered monocyclic heteroaryl. More preferably, it is a 5- or 6-membered monocyclic heteroaryl containing nitrogen or sulfur atoms (also known as a 5-6-membered heteroaryl). Examples of heteroaryl groups include, but are not limited to The polycyclic heteroaryl group also includes a monocyclic heteroaryl group fused to one or more aromatic groups, wherein the point of attachment is on the aromatic ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaryl ring system. The polycyclic heteroaryl group also includes a monocyclic heteroaryl group fused to one or more cycloalkyl or heterocyclic groups, wherein the point of attachment is on the monocyclic heteroaryl ring, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic heteroaryl ring system.

[0597] The term "aryl" refers to a monocyclic all-carbon aromatic ring (i.e., a monocyclic aromatic group) or a polycyclic aromatic ring system (i.e., a polycyclic aromatic group) having a conjugated π electron system, which has 6 to 14 (e.g., 6, 7, 8, 9, 10, 11, 12, 13 or 14) ring atoms (i.e., a 6- to 14-membered aromatic group). The aryl group is preferably an aromatic group having 6 to 10 ring atoms (i.e., a 6- to 10-membered aromatic group). The monocyclic aromatic group is, for example, a phenyl group. Non-limiting examples of the polycyclic aromatic group include: naphthyl, anthracenyl, phenanthrenyl, etc. The polycyclic aromatic group also includes a phenyl group fused with one or more heterocyclic groups or cycloalkyl groups, or a naphthyl group fused with one or more heterocyclic groups or cycloalkyl groups, wherein the connection point is on the phenyl group or naphthyl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the polycyclic aromatic ring system, non-limiting examples include:

[0598] wait.

[0599] Unless otherwise specified, when a group does not indicate which substituents it is substituted with, it is unsubstituted.

[0600] Unless otherwise specified, the term "alkyl" is used to denote a straight-chain or branched saturated hydrocarbon group. 1-6 Alkyl, more preferably C 1-4 Examples of the alkyl group include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, neopentyl, n-hexyl, and the like.

[0601] Unless otherwise specified, the term "hydroxyalkyl" is used to refer to an alkyl group substituted by one or more hydroxy groups. Preferably, it is an alkyl group substituted by one hydroxy group (i.e., -alkyl-OH). The "hydroxyalkyl" is preferably a hydroxy C 1-6 Alkyl, more preferably -C 1-6 Alkyl-OH.

[0602] Unless otherwise specified, the term "alkoxy" refers to an alkyl group connected through an oxygen bridge, that is, a group obtained by replacing the hydrogen atom of a hydroxy group with an alkyl group. 1-6 Alkoxy, more preferably C 1-4 Alkoxy. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy, and n-hexyloxy.

[0603] Unless otherwise specified, the term "halogen" means a fluorine, chlorine, bromine or iodine atom.

[0604] Unless otherwise specified, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen atom. 1-6 Halogenated alkyl, more preferably C 1-4 Examples of haloalkyl include, but are not limited to, monofluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl, and the like.

[0605] Unless otherwise specified, the term "haloalkoxy" refers to an alkoxy group in which one or more hydrogen atoms are replaced by a halogen atom.

[0606] Specifically, all combinations of substituents and / or variations thereof are permissible only if such combinations result in stable compounds.

[0607] Unless otherwise specified, the term "alkenyl" refers to a group derived from a straight-chain or branched alkene (or an alkyl group containing at least one carbon-carbon double bond, wherein the definition of alkyl is as described above) by removing a hydrogen atom, including "C 2-6 Alkenyl", "C 2-5 Alkenyl", "C 2-4 Alkenyl", "C 2-3"Alkenyl", specific examples include but are not limited to: -CH=CH2, -CH=CHCH3, -C(CH2)=CH2, -CH=CHCH2CH3, -CH2CH=CHCH3, etc.

[0608] Unless otherwise specified, the term "alkynyl" refers to a radical derived from a straight-chain or branched alkyne (or an alkyl group containing at least one carbon-carbon triple bond, wherein alkyl is as defined above) by removing a hydrogen atom, including "C 2-5 Alkynyl", "C 2-4 Alkynyl", "C 2-3 Specific examples include, but are not limited to: -C≡CH, -C≡CHCH3, CH≡CHCH2-, CH≡CC≡C-, etc.

[0609] The term "hydroxy" refers to -OH.

[0610] The term "amino" refers to -NH2.

[0611] The term "cyano" refers to -CN.

[0612] The term "oxo" or "oxo" refers to "=0".

[0613] The disclosed compounds may exist in specific stereoisomeric forms. The term "stereoisomer" refers to isomers having identical structures but different arrangements of atoms in space. It includes cis and trans (or Z and E) isomers, (-)- and (+)-isomers, (R)- and (S)-enantiomers, diastereomers, (D)- and (L)-isomers, tautomers, atropisomers, conformers and mixtures thereof (such as racemates, mixtures of diastereomers). The substituents in the disclosed compounds may have additional asymmetric atoms. All of these stereoisomers and their mixtures are included within the scope of the present disclosure. Optically active (-)- and (+)-isomers, (R)- and (S)-enantiomers and (D)- and (L)-isomers can be prepared by chiral synthesis, chiral reagents or other conventional techniques. An isomer of a compound disclosed herein can be prepared by asymmetric synthesis or chiral auxiliary, or, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), by forming a diastereomeric salt with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art to obtain the pure isomer. Furthermore, separation of enantiomers and diastereomers is typically accomplished by chromatography.

[0614] In the chemical structures of the compounds disclosed herein, the bond Indicates that the configuration is not specified, that is, if chiral isomers exist in the chemical structure, the bond Can be or include both For all carbon-carbon double bonds, even if only one configuration is named, both the Z and E configurations are included.

[0615] The compounds of the present disclosure include all suitable isotopic derivatives of the compounds thereof. The term "isotopic derivative" refers to a compound in which at least one atom is replaced by an atom having the same atomic number but a different atomic mass. Examples of isotopes that can be introduced into the compounds of the present disclosure include stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine, and iodine, for example, 2 H (deuterium, D), 3 H (tritium, T), 11 C. 13 C. 14 C. 15 N. 17 O. 18 O. 32 p、 33 p、 33 S. 34 S. 35 S. 36 S. 18 F. 36 Cl, 82 Br, 123 I. 124 I. 125 I. 129 I and 131 I, etc., preferably deuterium. Compared to non-deuterated drugs, deuterated drugs have advantages such as reduced toxic side effects, increased drug stability, enhanced therapeutic efficacy, and extended drug biological half-life. All isotopic composition changes of the compounds disclosed herein, whether radioactive or not, are included in the scope of this disclosure. Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom, wherein the deuterium replacement can be partial or complete, and partial deuterium replacement means that at least one hydrogen is replaced by at least one deuterium.

[0616] When a substituent's bond can cross-link to a ring, it means that the substituent can be bonded to any atom on the ring. Represents the substituent R c Substitution can occur at any position on ring C, and R c The number of is m.

[0617] The presence of a dash "-" in a substituent structure indicates the point of attachment for the substituent, for example -CH3 is attached through a C atom.

[0618] In the examples disclosed herein, the title compound names were derived from the compound structures using ChemDraw. In the event of inconsistencies between the compound name and the compound structure, the compound structure was determined using a combination of relevant information and reaction routes. If other methods were unavailable for confirmation, the given compound structure was used as the standard.

[0619] The preparation methods of some compounds disclosed herein refer to the preparation methods of the aforementioned similar compounds. Those skilled in the art should be aware that when using or referring to the preparation methods cited, the feed ratio of reactants, reaction solvent, reaction temperature, etc. can be appropriately adjusted according to the different reactants.

[0620] The compounds disclosed herein can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include, but are not limited to, the examples disclosed herein. DETAILED DESCRIPTION

[0621] The present disclosure is described in detail below by way of examples, but is not intended to limit the present disclosure in any way. While the present disclosure has been described in detail herein, including specific embodiments thereof, it will be apparent to those skilled in the art that various changes and modifications may be made to the specific embodiments of the present disclosure without departing from the spirit and scope of the invention.

[0622] In the embodiments of the present disclosure, the naming of the title compound is converted from the compound structure with the help of Chemdraw. If there is an inconsistency between the compound name and the compound structure, it can be determined by integrating relevant information and reaction routes; if it cannot be confirmed by other means, the given compound structure shall prevail. The preparation method of some compounds in the present disclosure quotes the preparation method of the aforementioned similar compounds. Those skilled in the art should know that when using or referring to the preparation method cited, the feed ratio of the reactants, the reaction solvent, the reaction temperature, etc. can be appropriately adjusted according to the different reactants. The compounds disclosed in the present disclosure can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, the embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present disclosure.

[0623] 1. Summary of experimental instruments

[0624] The structures of the compounds disclosed herein are confirmed by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS), or ultra-performance liquid chromatography-mass spectrometry (UPLC-MS).

[0625] NMR measurements were performed using a Bruker Neo 400M or Bruker Ascend 400 NMR instrument. The solvents used were deuterated dimethyl sulfoxide (DMSO-d6), deuterated methanol (CD3OD), deuterated chloroform (CDCl3), and deuterated water (D2O). The internal standard was tetramethylsilane (TMS). NMR chemical shifts (δ) are given in parts per million (ppm).

[0626] Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 1200&6120B single quadrupole mass spectrometer or a Shimadzu LC-20AD XR&MS2020 single quadrupole mass spectrometer (with electrospray ionization as the ion source).

[0627] HPLC analysis was performed using a Shimadzu 20AD XR high performance liquid chromatograph.

[0628] Preparative HPLC was performed using a GILSON GX281 333 / 334 Pump or a GILSON Trilution LC.

[0629] Chiral HPLC was performed using a Waters Arc 2998 with QDA.

[0630] Supercritical fluid chromatography (SFC) was performed using water acquity UPCC with QDA.

[0631] The starting materials and intermediates used in this disclosure can be synthesized according to methods known in the art or purchased commercially. Experimental procedures in the examples where specific conditions are not specified were generally performed under conventional conditions or as recommended by the raw material or product manufacturer. Reagents where the specific sources are not specified were purchased commercially.

[0632] The reaction progress in the examples can be monitored by conventional methods such as thin layer chromatography (TLC) and LC-MS. The eluent system for column chromatography and the developing solvent system for thin layer chromatography used for purification can be composed of one or more of the following solvents: dichloromethane, methanol, n-hexane, ethyl acetate, petroleum ether, ethyl acetate, acetone, dichloromethane, etc. The volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of alkaline or acidic reagents such as triethylamine, acetic acid, trifluoroformic acid, etc. can also be added for adjustment.

[0633] 2. Synthesis Example

[0634] Reference Example 1:

[0635] The preparation method refers to patent WO2021055744.

[0636] Reference compound:

[0637] The preparation method refers to the synthesis of compound A in patent WO2023183850A1.

[0638] The present disclosure calculates the lowest energy conformation (low-energy conformation) of Reference Example 1 using Spartan software using the ωB97X-D method under the 6-31G* basis set. In the low-energy conformation of Reference Example 1, the difluoromethylazathiazole fragment is in a coplanar state with the benzopyrazole core, and the S atom of the azathiazole fragment tends to deviate from the sulfonamide fragment (the dihedral angle corresponds to 0 degrees in the energy barrier diagram). In the active conformation binding mode of Reference Example 1 and PARG protein, the dihedral angle between the difluoromethylazathiazole fragment and the benzopyrazole core is only 1.5 degrees, which is highly consistent with the low-energy conformation of Reference Example 1, which fully explains the high binding activity of Reference Example 1 with PARG protein reported in the WO2021055744 patent. Generally speaking, when the structural difference between the lowest energy conformation (low-energy conformation) of a small molecule and its binding mode conformation (active conformation) in the protein is small, the energy lost when the molecule changes from the low-energy conformation to the active conformation is also small, the compound is easier to bind to the protein, and its corresponding binding activity is higher.

[0639] The synthetic routes of some embodiments of the present disclosure are as follows:

[0640] The synthesis of other example compounds in Table 1 of the present disclosure, such as Example 1, Example 2, Example 3, Example 4, Example 6, Example 7, Example 8, Example 9, Example 10, Example 11, Example 12, Example 13, Example 15, Example 16, Example 17, Example 18, Example 19, Example 20, Example 21, Example 22, Example 24, Example 25, Example 26, Example 28, Example 30, Example 31, Example 32, Example 33, Example 34, Example 35, Example 37, Example 38, Example 39, Example 41, Example 42, Example 43 and other recorded compounds, can be prepared by referring to any one of the above synthesis steps.

[0641] Specific compound synthesis example:

[0642] Example A001 and Example A002

[0643] Step 1: Synthesis of Compound A001_2

[0644] 005_1 (10.0 g, 42.0 mmol, 1.00 eq) and N-Boc piperazine (7.83 g, 42.0 mmol) were dissolved in N,N-dimethylacetamide (100 mL). N,N-diisopropylethylamine (27.1 g, 210 mmol) was added, and the reaction mixture was heated to 110°C and stirred for 16 hours. After the reaction was complete and cooled to room temperature, water (600 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined and washed with brine (100 mL x 3). The organic phases were dried over anhydrous sodium sulfate, filtered, and purified by column chromatography to obtain A001_2 (16.4 g).

[0645] MS (ESI) M / Z: 348.1, 350.2 [M-55] + .

[0646] 1 H NMR (400MHz, CDCl3-d): δ7.10–7.07(m,1H),7.04–7.03(m,1H),3.53(t,J=4.8Hz,4H),3.01(t,J=4.8Hz,4H),1.48(s,9H).

[0647] Step 2: Synthesis of Compound A001_3

[0648] To a solution of A001_2 (8.00 g, 19.8 mmol) in N,N-dimethylacetamide (80 mL) were added cesium carbonate (19.3 g, 59.3 mmol) and 5-(difluoromethyl)-1,3,4-thiadiazol-2-amine (4.49 g, 29.6 mmol). The reaction mixture was heated to 110°C and stirred under nitrogen for 16 hours. After the reaction was complete and cooled to room temperature, water (500 mL) was added to quench the reaction and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined and washed with brine (100 mL x 3). The organic phases were dried over anhydrous sodium sulfate, filtered, and purified by column chromatography to obtain A001_3 (6.7 g).

[0649] MS (ESI) M / Z: 533.1, 535.1 [MH] - .

[0650] Step 3: Synthesis of Compound A001_4

[0651] A001_3 (5.70 g, 10.6 mmol), 4-tert-butylbenzylmercaptan (2.11 g, 11.7 mmol), and N,N-diisopropylethylamine (3.44 g, 26.6 mmol) were dissolved in 1,4-dioxane (60 mL). The atmosphere was purged with nitrogen three times. Pd2(dba)3 (974 mg, 1.06 mmol) and Xantphos (1.23 g, 2.13 mmol, 0.20 eq) were then added. The atmosphere was purged with nitrogen three times. The reaction mixture was heated to 70°C and stirred for 1 hour. After the reaction was complete, the mixture was cooled to room temperature and quenched with water (200 mL). The mixture was then extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with brine (100 mL x 1). The organic phases were dried over anhydrous sodium sulfate, filtered, and purified by column chromatography to afford A001_4 (4.75 g).

[0652] MS (ESI) M / Z: 633.2 [MH] - .

[0653] 1 H NMR (400MHz, CDCl3-d): δ7.75(s,1H),7.37–7.27(m,4H),6.91(t,J=53.6Hz,1H),6.61(s, 1H), 4.22 (s, 2H), 3.53 (t, J = 4.8Hz, 4H), 2.94 (t, J = 4.8Hz, 4H), 1.48 (s, 9H), 1.31 (s, 9H).

[0654] Step 4: Synthesis of Compound A001_5

[0655] A001_4 (4.20 g, 6.62 mmol) was dissolved in ethanol (30 mL) and water (10 mL). Iron powder (1.85 g, 33.0 mmol) and ammonium chloride (1.77 g, 33.0 mmol) were added. The reaction mixture was heated to 80°C and stirred for 1.5 hours. After the reaction was complete, the mixture was cooled to room temperature and filtered through celite. The filtrate was diluted with water (100 mL) and extracted with ethyl acetate (50 mL x 3). The organic phases were combined and washed with brine (50 mL x 1). The organic phases were dried over anhydrous sodium sulfate, filtered and dried, and purified by column chromatography to obtain A001_5 (2.4 g).

[0656] MS (ESI) M / Z: 603.3 [MH] - .

[0657] 1H NMR (400MHz, DMSO-d6): δ9.81(s,1H),7.49-7.18(m,4H),7.11-7.09(m 2H), 6.55 (d, J = 2.0Hz, 1H), 4.91 (s, 2H), 3.93 (s, 2H), 3.52-3.38 (m, 4H), 2.68-2.55 (m, 4H), 1.41 (s, 9H), 1.23 (s, 9H).

[0658] Step 5: Synthesis of Compound A001_6

[0659] A001_5 (430 mg, 711 μmol) was dissolved in tetrahydrofuran (10 mL), and carbonyldiimidazole (173 mg, 1.07 mmol, 1.50 eq) was added. The reaction mixture was heated to 70°C and stirred for 1 hour. After the reaction was complete, the mixture was cooled to room temperature and concentrated under reduced pressure to obtain a crude product. The crude product was slurried with methyl tert-butyl ether (5 mL) at room temperature and filtered to obtain the filter cake A001_6 (360 mg).

[0660] MS (ESI) M / Z: 629.2 [MH] - .

[0661] 1 H NMR (400MHz, DMSO-d6): δ12.11(s,1H),8.10(s,1H),7.61(t,J=53.2Hz,1H),7.29(d,J=8.4Hz,2H),7.19(d,J=8. 0Hz,2H),7.03(s,1H),6.66(s,1H),4.13(s,2H),3.50–3.48(m,4H),2.79–2.77(m,4H),1.43(s,9H),1.23(s,9H).

[0662] Step 6: Synthesis of Compound A001_7

[0663] A001_6 (250 mg, 396 μmol) was dissolved in acetic acid (2.5 mL), water (1.25 mL), and dichloromethane (2.5 mL). The mixture was cooled to 0°C in an ice-salt bath, and N-chlorosuccinimide (159 mg, 1.19 mmol, 3.00 eq) was added portionwise. After the addition was complete, the reaction solution was slowly warmed to 20°C and stirred for 4 hours. After the reaction was complete, the temperature was lowered to 0°C, and saturated aqueous sodium bicarbonate solution was slowly added to adjust the pH to ~5. The mixture was then extracted with dichloromethane (5 mL x 3). The organic phases were combined and washed with brine (10 mL x 1). The organic phases were dried over anhydrous sodium sulfate, filtered, and spun down to dryness to afford A001_7 (220 mg), which was used directly in the next step.

[0664] MS (ESI) M / Z: 549.2, 551.4 [MH] - .

[0665] Step 7: Synthesis of Compound A001_8

[0666] 1-Methylcyclopropylamine hydrochloride (141 mg, 1.31 mmol) and N,N-diisopropylethylamine (253 mg, 1.96 mmol) were dissolved in dichloromethane (0.9 mL). A solution of A001_7 (180 mg, 327 μmol) in dichloromethane (0.9 mL) was added, and the reaction mixture was stirred at 20°C for 1 hour. After the reaction was complete, water (5 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (5 mL × 3). The organic phases were combined and washed with brine (5 mL × 1). The organic phases were dried over anhydrous sodium sulfate, filtered, and purified by column chromatography to obtain A001_8 (110 mg).

[0667] MS (ESI) M / Z: 584.2 [MH] - .

[0668] 1 H NMR (400MHz, DMSO-d6): δ12.44(s,1H),8.52(d,J=1.2Hz,1H),8.08(s,1H),7.63(t,J=53.2Hz,1H),7.37(d,J=1. 2Hz,1H),3.58–3.56(m,4H),2.98–2.96(m,4H),1.44(s,9H),1.07(s,3H),0.64–0.62(m,2H),0.39–0.36(m,2H).

[0669] Step 8: Synthesis of Compound A001

[0670] A001_8 (60 mg, 102 μmol) was dissolved in ethyl acetate (1 mL), and methanolic hydrochloric acid (4 M, 2 mL) was added. The reaction mixture was stirred at 20°C for 1 hour. After the reaction was complete, the reaction mixture was concentrated under reduced pressure to obtain a crude product (50 mg, hydrochloride salt). 20 mg of the crude product was purified by preparative HPLC (hydrochloric acid conditions, Phenomenex luna C18 column) to obtain A001 (11.81 mg, hydrochloride salt).

[0671] MS (ESI) M / Z: 486.0 [M+H] + .

[0672] 1H NMR (400MHz, DMSO-d6): δ12.51(s,1H),9.20–8.96(m,2H),8.55(d,J=1.2Hz,1H),8.17(s,1H),7.64(t,J=53.2 Hz,1H),7.39(s,1H),3.48–3.42(m,4H),3.42–3.38(m,4H),1.07(s,3H),0.64–0.62(m,2H),0.39–0.37(m,2H).

[0673] Step 9: Synthesis of Compound A002

[0674] A001 (50 mg, 95.8 μmol, hydrochloride) and triethylamine (48.5 mg, 479 μmol) were dissolved in N,N-dimethylformamide (0.5 mL), and 2-methylpropanoyl chloride (12.3 mg, 115 μmol) was added. The reaction mixture was stirred at 20°C for 1 hour. After the reaction was complete, water (0.1 mL) was added to quench the reaction mixture, and the product was purified by HPLC (neutral conditions, Waters Xbridge Prep OBD C18 column) to obtain A002 (27.2 mg).

[0675] MS (ESI) M / Z: 556.2 [M+H] + .

[0676] 1 H NMR (400MHz, DMSO-d6): δ12.48(s,1H),8.52(d,J=1.2Hz,1H),8.07(s,1H),7.62(t,J=53.2Hz,1H),7.35(d,J =1.2Hz,1H),3.74–3.70(m,4H),3.02–2.91(m,5H),1.05–1.03(m,9H),0.64–0.61(m,2H),0.38–0.35(m,2H).

[0677] Example A003

[0678] Step 1: Synthesis of A003

[0679] A002 (15 mg, 27.0 μmol) and potassium carbonate (7.46 mg, 54.0 μmol) were dissolved in N,N-dimethylformamide (0.2 mL). Methyl iodide (5.75 mg, 40.5 μmol) was added in one portion at 20°C. The reaction mixture was stirred at 20°C for 1 hour. After completion, the reaction was quenched by the addition of 2 mL of water and extracted with ethyl acetate (2 mL x 3). The combined organic phases were washed with brine (2 mL x 1). The organic phases were dried over anhydrous sodium sulfate, filtered, and dried. The crude product was purified by preparative HPLC (neutral conditions, Waters Xbridge Prep OBD C18 column) to afford A003 (1.2 mg).

[0680] MS (ESI) M / Z: 570.2 [M+H] + .

[0681] 1 H NMR (400MHz, DMSO-d6): δ8.66(d,J=1.6Hz,1H),8.13(s,1H),7.77–7.50(m,2H),4.52–4.50(m,1H),4.07–4.06(m,1H),3.80(s,3H),3 .45–3.42(m,1H),3.18–3.16(m,2H),2.98–2.80(m,3H),2.71–2.68(m,1H),1.08–1.05(m,9H),0.64–0.62(m,2H),0.40–0.37(m,2H).

[0682] Example A004

[0683] Step 1: Synthesis of Compound A004

[0684] A001 (7 mg, 14.4 μmol) and triethylamine (14.6 mg, 144 μmol, 10.00 eq) were dissolved in DCM (2.0 mL), and dimethylaminoformyl chloride (15.5 mg, 144 μmol) was added. The reaction mixture was stirred at 23°C for 20 hours. Water (5 mL) was added to quench the reaction mixture, and the reaction solution was extracted three times with ethyl acetate. The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by preparative purification (acidic conditions, 0.1% FA, chromatographic column: YMC-Actus Triart C18 ExRS) to obtain A004 (4.0 mg).

[0685] MS (ESI) M / Z: 557.1 [M+H] + .

[0686] 1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),7.89(s,1H),7.58(t,J=53.4Hz,1H),7.23(s,1H),3.36–3 .32(m,4H),3.17–3.09(m,4H),2.79(s,6H),1.04(s,3H),0.66–0.58(m,2H),0.37–0.31(m,2H).

[0687] Example A005 and Example A006

[0688] Table 2

[0689] Example A007, Example A008, Example A009

[0690] Step 1: Synthesis of Compound A007_2

[0691] A001_1 (3.00 g, 12.6 mmol) and N,N-diisopropylethylamine (8.15 g, 63.0 mmol) were dissolved in N,N-dimethylacetamide (30 mL). Tert-butyl (2S,6S)-2,6-dimethylpiperazine-1-carboxylate (2.70 g, 12.6 mmol) was added. The reaction mixture was heated to 110°C and stirred for 3 hours. After cooling to room temperature, water (100 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (30 mL x 3). The organic phase was washed with brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and dried. Purification by column chromatography afforded A007_2 (5.06 g).

[0692] MS (ESI) M / Z: 332.2, 334.2 [M-Boc] + .

[0693] 1 H NMR (400MHz, DMSO-d6): δ7.21–7.18(m,1H),7.14(s,1H),4.06–4.03(m,2H),3.79–3.75(m, 2H), 2.99–2.96 (m, 2H), 1.42 (s, 9H), 1.15 (d, J = 6.4Hz, 6H).

[0694] Step 2: Synthesis of Compound A007_3

[0695] To a solution of A007_2 (5.06 g, 11.7 mmol) in N,N-dimethylacetamide (50 mL) were added cesium carbonate (11.4 g, 35.1 mmol) and 5-(difluoromethyl)-1,3,4-thiadiazol-2-amine (2.65 g, 17.6 mmol). The reaction mixture was heated to 110°C and stirred for 16 hours. After cooling to room temperature, the reaction was quenched by the addition of water (100 mL). The mixture was extracted with ethyl acetate (30 mL x 3). The organic phase was washed with brine (50 mL x 3), dried over anhydrous sodium sulfate, filtered, and dried. Purification by column chromatography afforded A007_3 (3.65 g).

[0696] MS (ESI) M / Z: 561.1, 563.1 [MH] - .

[0697] Step 3: Synthesis of Compound A007_4

[0698] A007_3 (3.10 g, 5.50 mmol), 4-tert-butylbenzylmercaptan (1.09 g, 6.05 mmol), and N,N-diisopropylethylamine (1.78 g, 13.8 mmol) were dissolved in 1,4-dioxane (31 mL). The atmosphere was purged with nitrogen three times. Pd2(dba)3 (504 mg, 550 μmol) and Xantphos (637 mg, 1.10 mmol) were then added, and the atmosphere was purged with nitrogen three times. The reaction mixture was heated to 70°C and stirred for 1 hour. After cooling to room temperature, the reaction was quenched by the addition of water (50 mL). The mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was washed with brine (50 mL × 1), dried over anhydrous sodium sulfate, filtered, and dried. Purification by column chromatography afforded A007_4 (3.65 g).

[0699] MS (ESI) M / Z: 663.2 [M+H] + .

[0700] Step 4: Synthesis of Compound A007_5

[0701] A007_4 (3.65 g, 5.51 mmol) was dissolved in ethanol (30 mL) and water (10 mL). Iron powder (1.54 g, 27.5 mmol) and ammonium chloride (1.47 g, 27.5 mmol) were added. The reaction mixture was heated to 80°C and stirred for 1.5 hours. After cooling to room temperature, it was filtered through celite. The filtrate was diluted with water (50 mL) and extracted with ethyl acetate (50 mL x 3). The organic phase was washed with brine (50 mL x 1), dried over anhydrous sodium sulfate, filtered, and dried. Purification by column chromatography afforded A007_5 (2.08 g).

[0702] MS (ESI) M / Z: 633.2 [M+H]+ .

[0703] 1 H NMR (400MHz, DMSO-d6): δ9.81(s,1H),7.46–7.19(m,4H),7.14–7.12(m,2H),6.59(d,J=2.0Hz,1H),4.82(s,2 H),3.96–3.92(m,4H),2.99–2.96(m,2H),2.48–2.44(m,2H),1.42(s,9H),1.37(d,J=6.4Hz,6H),1.24(s,9H).

[0704] Step 5: Synthesis of Compound A007_6

[0705] A007_5 (600 mg, 948 μmol) was dissolved in tetrahydrofuran (12 mL), and carbonyldiimidazole (231 mg, 1.42 mmol) was added. The reaction mixture was heated to 70°C and stirred for 2 hours. After cooling to room temperature, the reaction was quenched by adding water (10 mL). The mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with brine (20 mL × 1), dried over anhydrous sodium sulfate, filtered, and dried. Purification by column chromatography afforded A007_6 (720 mg).

[0706] MS (ESI) M / Z: 657.3 [MH] - .

[0707] 1 H NMR (400MHz, DMSO-d6): δ11.74(s,1H),7.97(s,1H),7.61(t,J=53.2Hz,1H),7.31–7.24(m,4H),6.58(s,1H),4.16– 4.14(m,2H),4.07–4.02(m,2H),3.76–3.73(m,2H),2.88–2.86(m,2H),1.43(s,9H),1.23(s,9H),1.19–1.17(m,6H).

[0708] Step 6: Synthesis of Compound A007_7

[0709] A007_6 (570 mg, 865 μmol) was dissolved in acetic acid (0.9 mL), water (1.8 mL), and acetonitrile (6.3 mL). The mixture was cooled to 0°C in an ice-salt bath, and dichlorohydantoin (341 mg, 1.73 mmol) was added portionwise. After the addition was complete, the reaction solution was slowly warmed to 20°C and stirred for 2 hours. After cooling to 0°C again, water (10 mL) was added to quench the reaction. The mixture was extracted with dichloromethane (5 mL x 3). The organic phase was washed with brine (10 mL x 1), dried over anhydrous sodium sulfate, filtered, and dried. A007_7 (500 mg) was obtained, and the crude product was used directly in the next step.

[0710] MS (ESI) M / Z: 577.2 [MH] - .

[0711] Step 7: Synthesis of Compound A007_8

[0712] 1-Methylcyclopropylamine hydrochloride (372 mg, 3.45 mmol) and N,N-diisopropylethylamine (670 mg, 5.18 mmol) were dissolved in dichloromethane (5 mL). A solution of A007_7 (500 mg, 864 μmol) in dichloromethane (3 mL) was added. The reaction mixture was stirred at 20°C for 2 hours. Water (10 mL) was added to quench the reaction and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was washed with brine (10 mL × 1), dried over anhydrous sodium sulfate, filtered, and dried. Purification by column chromatography afforded A007_8 (260 mg).

[0713] MS (ESI) M / Z: 612.3 [MH] - .

[0714] 1 H NMR (400MHz, DMSO-d6): δ12.11(s,1H),8.41(s,1H),8.11(s,1H),7.64(t,J=53.2Hz,1H),7.27(s,1H),4.14–4.11(m,2H), 3.96–3.93(m,2H),3.07–3.04(m,2H),1.45(s.9H),1.26–1.23(m,6H),1.08(s.3H),0.66–0.63(m,2H),0.38–0.35(m,2H).

[0715] Step 8: Synthesis of Compound A007

[0716] A007_8 (30 mg, 48.9 μmol) was dissolved in ethyl acetate (0.3 mL), and ethyl acetate hydrochloride (4 M, 1 mL) was added. The reaction mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain a crude product (25 mg, salt), which was used directly in the next step. 20 mg of the crude product was purified by preparative chromatography (salt, Phenomenex luna C18 column) to obtain A007 (9.91 mg, hydrochloride).

[0717] MS (ESI) M / Z: 514.3 [M+H] + .

[0718] 1 H NMR (400MHz, DMSO-d6): δ12.47(s,1H),9.11(s,2H),8.55(s,1H),8.18(s,1H),7.64(t,J=53.2Hz,1H),7.38(s,1H),3.93–3 .91(m,2H),3.41–3.38(m,2H),2.82–2.78(m,2H),1.35(d,J=6.4Hz,6H),1.08(s,3H),0.64–0.62(m,2H),0.40–0.37(m,2H).

[0719] Step 9: Synthesis of Compound A008

[0720] A007 (17 mg, 30.9 μmol) and N,N-diisopropylethylamine (24.0 mg, 185 μmol) were dissolved in N-methylpyrrolidone (0.2 mL), and dimethylcarbamoyl chloride (4.99 mg, 46.4 μmol, 1.50 eq) was added. The reaction mixture was heated to 35°C and stirred for 16 hours. Water (0.1 mL) was added to quench the reaction mixture. A008 (9.64 mg) was obtained by preparative chromatography (neutral conditions, Waters Xbridge Prep OBD C18 column).

[0721] MS (ESI) M / Z: 585.2 [M+H] + .

[0722] 1H NMR (400MHz, DMSO-d6): δ12.42(s,1H),8.51(s,1H),8.09(s,1H),7.63(t,J=53.2Hz,1H),7.35(s,1H),3.74–3.70( m,2H),3.28–3.25(m,2H),2.91(s,6H),2.62–2.60(m,2H),1.09–1.07(m,9H)0.64–0.61(m,2H),0.39–0.36(m,2H).

[0723] Step 10: Synthesis of Compound A009

[0724] A007 (20 mg, 36.4 μmol) and triethylamine (22.1 mg, 218 μmol) were dissolved in N,N-dimethylacetamide (0.1 mL), and 2-methylpropanoyl chloride (4.26 mg, 40.0 μmol) was added. The reaction mixture was stirred at 20°C for 1 hour. Water (0.1 mL) was added to quench the reaction mixture. Preparative purification (neutral conditions, Waters Xbridge Prep OBD C18 column) afforded A009 (9.05 mg).

[0725] MS (ESI) M / Z: 584.2 [M+H] + .

[0726] 1 H NMR (400MHz, DMSO-d6): δ12.01(s,1H),8.38(s,1H),8.06(s,1H),7.63(t,J=53.2Hz,1H),7.25(s,1H),4.32–4.30(m,2H),4.13– 4.10(m,2H),3.22–3.19(m,2H),2.82–2.79(m,1H),1.26–1.25(m,6H),1.07–1.05(m,9H),0.68–0.63(m,2H),0.37–0.35(m,2H).

[0727] Example A010, Example A011, Example A012

[0728] Step 1: Synthesis of Compound A010_9

[0729] A007_8 (140 mg, 228 μmol) and potassium carbonate (63.1 mg, 456 μmol) were dissolved in N,N-dimethylformamide (2 mL), and iodomethane (48.6 mg, 342 μmol) was added. The reaction mixture was stirred at 20°C for 1 hour. Water (2 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (2 mL × 3). The organic phase was washed with brine (2 mL × 1), dried over anhydrous sodium sulfate, filtered, and dried. Purification on preparative silica gel plates afforded A010_9 (50 mg).

[0730] MS (ESI) M / Z: 626.3 [MH] - .

[0731] Step 2: Synthesis of Compound A010

[0732] A010_9 (50 mg, 79.7 μmol) was dissolved in ethyl acetate (1 mL), and ethyl acetate hydrochloride (4 M, 2 mL) was added. The reaction mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated under reduced pressure to obtain crude A010 (55 mg, hydrochloride salt), which was used directly in the next step. 15 mg of the crude product was purified by preparative chromatography (hydrochloric acid, Phenomenex luna C18 column) to obtain A010 (7.31 mg, hydrochloride salt).

[0733] MS (ESI) M / Z: 528.1 [M+H] + .

[0734] 1 H NMR (400MHz, DMSO-d6): δ9.25(s,2H),8.71(s,1H),8.28(s,1H),7.78–7.51(m,2H),3.88–3.72(m,2H),3.78(s,3H),3.38–3.35(m,2H), 3.10–3.06(m,1H),2.65–2.58(m,1H),1.51(d,J=5.6Hz,3H),1.25(d,J=4.4Hz,3H),1.09(s,3H),0.64–0.62(m,2H),0.41–0.38(m,2H).

[0735] Step 3: Synthesis of Compound A011

[0736] A010 (15 mg, 26.6 μmol) and N,N-diisopropylethylamine (20.6 mg, 160 μmol, 6.00 eq) were dissolved in N-methylpyrrolidone (0.2 mL), and dimethylcarbamoyl chloride (4.29 mg, 38.9 μmol, 1.50 eq) was added. The reaction mixture was heated to 35°C and stirred for 16 hours. Water (0.1 mL) was added to quench the reaction mixture. A011 (6.65 mg) was obtained by preparative chromatography (neutral conditions, Waters Xbridge Prep OBD C18 column).

[0737] MS (ESI) M / Z: 599.2 [M+H] + .

[0738] 1 H NMR (400MHz, DMSO-d6): δ8.66(s,1H),8.17(s,1H),7.77–7.51(m,2H),3.82(s,3H),3.68–3.60(m,2H),3.27–3.19(m,2H),2.99–2.9 6(m,1H),2.92(s,6H),2.33–2.30(m,1H),1.23–1.19(m,3H),1.08(s,3H),1.00–0.97(m,3H),0.64–0.62(m,2H),0.40–0.38(m,2H).

[0739] Step 4: Synthesis of Compound A012

[0740] A010 (15 mg, 26.6 μmol) and triethylamine (16.2 mg, 160 μmol, 6.00 eq) were dissolved in N,N-dimethylacetamide (0.1 mL), and 2-methylpropanoyl chloride (4.25 mg, 39.9 μmol, 1.50 eq) was added. The reaction mixture was stirred at 20°C for 1 hour. Water (0.1 mL) was added to quench the reaction mixture. A012 (4.96 mg) was obtained by preparative chromatography (neutral conditions, Waters Xbridge Prep OBD C18 column).

[0741] MS (ESI) M / Z: 598.2 [M+H] + .

[0742] 1H NMR (400MHz, DMSO-d6): δ8.60(s,1H),8.15(s,1H),7.77–7.51(m,2H),4.27–4.23(m,2H),3.79–3.75(m,5H),3.04 –3.02(m,2H),2.89–2.82(m,1H),1.32(d,J=7.0Hz,6H),1.08–1.04(m,9H),0.66–0.60(m,2H),0.41–0.35(m,2H).

[0743] Example A013 and Example A014

[0744] Table 3

[0745] Example A017, Example A018, Example A019 Table 4

[0746] Example A023 Table 5

[0747] Example A024 Table 6

[0748] Example A026 Table 7

[0749] Example A027 Table 8

[0750] Example A028 Table 9

[0751] Example A029 Table 10

[0752] Example A030

[0753] Table 11

[0754] Example B001 and Example B002

[0755] Step 1: Synthesis of compound B001_6

[0756] A001_5 (800 mg, 1.32 mmol) was dissolved in trimethyl orthoformate (8.00 mL), and p-toluenesulfonic acid (22.7 mg, 132 μmol, 0.10 eq) was added. The reaction mixture was heated to 100°C and stirred for 1 hour. After the reaction was complete, it was cooled to room temperature, quenched by the addition of water (20 mL), and extracted with ethyl acetate (20 mL x 3). The organic phases were combined and washed with brine (30 mL x 3). The organic phases were dried over anhydrous sodium sulfate, filtered, and dried to dryness to obtain B001_6 (700 mg), which was used directly in the next step.

[0757] MS (ESI) M / Z: 615.2 [M+H] + .

[0758] 1 H NMR (400MHz, DMSO-d6): δ8.80(s,1H),7.80–7.53(m,2H),7.33–7.27(m,4H),6.60(s ,1H),4.23(s,2H),3.51–3.48(m,4H),3.37–3.35(m,4H),1.43(s,9H),1.24(s,9H).

[0759] Step 2: Synthesis of compound B001_7

[0760] B001_6 (315 mg, 512 μmol) was dissolved in dichloromethane (4.00 mL), acetic acid (4.00 mL), and water (2.00 mL). The mixture was cooled to 0°C in an ice-salt bath, and N-chlorosuccinimide (205 mg, 1.54 mmol) was added portionwise. After the addition was complete, the reaction solution was slowly warmed to 20°C and stirred for 4 hours. Two reactions were set up in parallel. After the reaction was complete, the two parallel reactions were combined. The reaction solution was cooled to 0°C again, and saturated aqueous sodium bicarbonate solution was slowly added to adjust the pH to ~5. The mixture was extracted with dichloromethane (20 mL x 2). The organic phases were combined and washed with brine (30 mL x 1). The organic phases were dried over anhydrous sodium sulfate, filtered, and dried to give B001_7 (548 mg), which was used directly in the next step.

[0761] MS (ESI) M / Z: 479.2, 481.1 [M-55] + .

[0762] Step 3: Synthesis of compound B001_8

[0763] 1-Methylcyclopropylamine hydrochloride (440 mg, 4.10 mmol) and N,N-diisopropylethylamine (529 mg, 4.10 mmol) were dissolved in dichloromethane (5.00 mL). After cooling to 0°C, a dichloromethane solution (5 mL) of B001_7 (548 mg, 1.02 mmol) was slowly added dropwise. After the addition was complete, the reaction solution was slowly warmed to 20°C and stirred for 1 hour. After the reaction was complete, water (20 mL) was added to quench the reaction and the mixture was extracted with dichloromethane (20 mL x 2). The organic phases were combined and washed with brine (30 mL x 1). The organic phases were dried over anhydrous sodium sulfate, filtered and dried, and purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 1 / 1) to obtain B001_8 (100 mg).

[0764] MS (ESI) M / Z: 514.1 [M-55] + .

[0765] 1 H NMR (400MHz, DMSO-d6): δ9.04(s,1H),8.24(s,1H),8.13(s,1H),7.67(t,J=53.2Hz,1H),7.20 (s,1H),3.57(s,8H),1.43(s,9H),1.04(s,3H),0.63(t,J=5.6Hz,2H),0.37(t,J=5.6Hz,2H).

[0766] Step 4: Synthesis of compound B001

[0767] B001_8 (60.0 mg, 105 μmol, 1.00 eq) was dissolved in methanol (0.5 mL), and methanolic hydrochloric acid (4 M, 2 mL) was added dropwise. The reaction mixture was stirred at 20°C for 2 hours. After the reaction was complete, the reaction mixture was concentrated under reduced pressure to obtain B001 (54.43 mg, hydrochloride salt).

[0768] MS (ESI) M / Z: 470.0 [M+H] + .

[0769] 1 H NMR (400MHz, DMSO-d6): δ9.24(s,1H),9.09(s,1H),8.30(s,1H),8.20(s,1H),7.68(t,J=53.0Hz,1H),7 .26(s,1H),3.83(t,J=4.8Hz,4H),3.35(s,4H),1.05(s,3H),0.63(t,J=5.6Hz,2H),0.39-0.36(m,2H).

[0770] Step 5: Synthesis of Compound B002

[0771] B001 (37.0 mg, 73.1 μmol, hydrochloride) and triethylamine (29.6 mg, 292 μmol) were dissolved in dichloromethane (1.00 mL), cooled to 0°C, and 2-methylpropanoyl chloride (15.6 mg, 146 μmol) was added. After the addition was complete, the reaction solution was slowly warmed to 20°C and stirred for 1 hour. After the reaction was complete, water (5 mL) was added to quench the reaction and the mixture was extracted with dichloromethane (5 mL x 2). The organic phases were combined, washed with brine (5 mL x 1), dried over anhydrous sodium sulfate, filtered, and the crude product was purified on a preparative silica gel plate to obtain B002 (23.38 mg).

[0772] MS (ESI) M / Z: 540.1 [M+H] + .

[0773] 1 H NMR (400MHz, DMSO-d6): δ9.05(s,1H),8.25(s,1H),8.14(s,1H),7.67(t,J=53.2Hz,1H),7.20(s,1H),3.76-3.7 1(m,4H),3.62-3.57(m,4H),2.99-2.92(m,1H),1.05-1.03(m,9H),0.64(t,J=5.6Hz,2H),0.37(t,J=5.6Hz,2H).

[0774] Example B003

[0775] Step 1: Synthesis of compound B003

[0776] B001 (8 mg, 15.8 μmol) and triethylamine (16.0 mg, 158 μmol) were dissolved in DCM (2.0 mL), and dimethylaminoformyl chloride (17.0 mg, 158 μmol, 10 eq) was added. The reaction mixture was stirred at 23 ° C for 20 hours. Water (5 mL) was added to quench the reaction mixture, and the reaction solution was extracted three times with ethyl acetate. The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by preparative purification (acidic conditions, 0.1% FA, chromatographic column: YMC-Actus Triart C18 ExRS) to give B003 (2.1 mg).

[0777] MS (ESI) M / Z: 541.1 [M+H] + .

[0778] 1H NMR (400MHz, DMSO-d6)9.04(s,1H),8.25(d,J=1.4Hz,1H),8.16(s,1H),7.68(t,J=53.0Hz,1H),7.22(d,J=1.6 Hz,1H),3.66–3.56(m,4H),3.40–3.30(m,4H),2.81(s,6H),1.05(s,3H),0.67–0.61(m,2H),0.40–0.35(m,2H).

[0779] Example B004, Example B005, Example B006

[0780] Table 12

[0781] Example B007, Example B008

[0782] Step 1: Synthesis of compound B007_6

[0783] A001_5 (100 mg, 165 mmol) was dissolved in a mixture of dichloromethane (2 mL) and tert-butanol (0.4 mL), and cyanogen bromide (101 mg, 960 mmol, 5.81 eq) was added. The reaction solution was stirred at 20°C for 12 hours. After cooling the reaction solution to 0°C, saturated aqueous sodium bicarbonate solution was slowly added to adjust the pH to ~7. The solution was extracted with dichloromethane (10 mL × 3). The organic phase was washed with saturated brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and spin-dried to obtain B007_6 (138 mg). The crude product was used directly in the next step.

[0784] MS (ESI) M / Z: 630.2 [M+H] + .

[0785] 1 H NMR (400MHz, DMSO-d6): δ7.65(t,J=52.8Hz,1H),7.29–7.26(m,3H),7.25–7.22(m,2H),7.18–7.16 (m,2H),6.46(s,1H),4.08(s,2H),3.47–3.45(m,4H),3.19–3.16(m,4H),1.43(s,9H),1.23(s,9H).

[0786] Step 2: Synthesis of compound B007_7

[0787] B007_6 (100 mg, 158.7 mmol) was dissolved in a mixture of dichloromethane (1.5 mL), acetic acid (1.5 mL), and water (0.75 mL). The reaction mixture was cooled to 0°C and N-chlorosuccinimide (83 mg, 624 mmol) was added portionwise. After the addition was complete, the reaction mixture was slowly heated to 20°C and stirred for 2 hours. After cooling to 0°C, saturated aqueous sodium bicarbonate was slowly added to adjust the pH to ~6. The mixture was extracted with dichloromethane (20 mL x 3). The organic phase was washed with brine (20 mL x 3), dried over anhydrous sodium sulfate, filtered, and dried. B007_7 (87 mg) was obtained, and the crude product was used directly in the next step.

[0788] MS (ESI) M / Z: 548.2, 550.1 [MH] - .

[0789] Step 3: Synthesis of Compound B007_8

[0790] 1-Methylcyclopropylamine hydrochloride (68 mg, 632.7 μmol) and N,N-diisopropylethylamine (82 mg, 632.7 μmol) were dissolved in dichloromethane (2 mL). After cooling to 0°C, a dichloromethane solution (1 mL) of B007_7 (87 mg, 158 mmol) was slowly added dropwise. After the addition was complete, the reaction solution was slowly warmed to 20°C and stirred for 1 hour. Water (20 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (20 mL x 2). The organic phase was washed with brine (30 mL x 1), dried over anhydrous sodium sulfate, filtered, and dried. Purification on a silica gel plate afforded B007_8 (7 mg), which was used directly in the next step.

[0791] MS (ESI) M / Z: 583.3 [MH] - .

[0792] Step 4: Synthesis of compound B007

[0793] B007_8 (5 mg, 8.55 μmol) was dissolved in methanol (0.5 mL). 4 M methanolic hydrochloric acid (2 mL) was added dropwise. The reaction mixture was stirred at 20°C for 2 hours. LCMS monitored the reaction for completion. The reaction mixture was dried with nitrogen and purified by preparative chromatography (hydrochloric acid, Phenomenex luna C18 column) to afford B007 (1.36 mg, hydrochloride).

[0794] MS (ESI) M / Z: 485.1 [M+H] + .

[0795] 1H NMR (400MHz, DMSO-d6): δ9.02(s,2H),7.93(s,1H),7.69-7.54(m,4H),7.14(s,1H),3. 65–3.62(m,4H),3.35–3.31(m,4H),1.03(s,3H),0.63-0.61(m,2H),0.37-0.34(m,2H).

[0796] Step 5: Synthesis of Compound B008

[0797] B007 (9 mg, 17.2 μmol) and triethylamine (20.9 mg, 207 μmol) were dissolved in N,N-dimethylformamide (0.75 mL), cooled to 0°C, and dimethylcarbamoyl chloride (2.2 mg, 20.7 μmol) was added. After the addition was complete, the reaction solution was slowly warmed to 20°C and stirred for 1 hour. LCMS confirmed the reaction was complete. Water (5 mL) was added to quench the reaction, and the mixture was extracted with dichloromethane (5 mL x 2). The organic phase was washed with brine (5 mL x 1), dried over anhydrous sodium sulfate, filtered, and dried. Purification by preparative chromatography (neutral conditions, Waters Xbridge Prep OBD C18 column) afforded B008 (6.53 mg).

[0798] MS (ESI) M / Z: 556.2 [M+H] + .

[0799] 1 H NMR (400MHz, DMSO-d6): δ7.89(s,1H),7.82-7.53(m,2H),7.49(s,2H),7.12(s,1H),3.43-3.4 1(m,4H),3.33–3.30(m,4H),2.79(s,6H),1.01(s,3H),0.62-0.59(m,2H),0.35-0.32(m,2H).

[0800] Example B009, Example B010, Example B011

[0801] Table 13

[0802] Example C001, Example C002

[0803] Step 1: Synthesis of compound C001_4a

[0804] A001_3 (2.00 g, 3.74 mmol), methyl 3-mercaptopropionate (493 mg, 4.11 mmol), and N,N-diisopropylethylamine (1.55 g, 11.9 mmol) were dissolved in 1,4-dioxane (20 mL). The atmosphere was purged with nitrogen three times. Pd2(dba)3 (342 mg, 374 μmol, 0.10 eq) and Xantphos (432 mg, 747 μmol, 0.20 eq) were then added and the atmosphere was purged with nitrogen three times. The reaction mixture was heated to 85°C and stirred for 2 hours. Three parallel reactions were performed and then combined. After cooling to room temperature, the reaction was quenched by the addition of water (200 mL) and extracted with ethyl acetate (100 mL...

Claims

1. A compound represented by formula (IA) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, in, x 1 Selected from C, CR x1 , N, where R x1 Selected from H, halogen, hydroxyl, -NR n1 R n2 , C 1-4 Alkyl, -OC 1-4 alkyl; x 2 Selected from CR x2 、N、C(=O)、C(=CR x2 ), where R x2 Selected from H, halogen, hydroxyl, amino, cyano, C 2-6 Alkenyl, C 2- 6 alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, -NR n1 R n2 , -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; x 3 Selected from C, CR x3 , N, where R x3 Selected from H, halogen, hydroxyl, -NR n1 R n2 , C 1-4 Alkyl, -OC 1-4 alkyl; x 4 Selected from C, CR x4 , N, where R x4 Selected from H, halogen, hydroxyl, -NR n1 R n2 , C 1-4 Alkyl, -OC 1-4 alkyl; x 5 Selected from C, CR x5 , N, where R x5 Selected from H, halogen, hydroxyl, -NR n1 R n2 , C 1-4 Alkyl, -OC 1-4 alkyl; x 6 Selected from CR x6 、N、C(=O)、C(=CR x6 ), where R x6 Selected from H, halogen, hydroxyl, cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, -NR n1 R n2 , -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd Wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; x 7 Selected from C, CR x7 , N, where R x7 Selected from H, halogen, hydroxyl, -NR n1 R n2 , C 1-4 Alkyl, -OC 1-4 alkyl; x 8 Selected from N, O, CR x8 , CR x8 R x8 NR x8 、S(O) p , C(=O), C(=CR x8 ), where R x8 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR n1 R n2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1- 6 Alkoxy, Hydroxyl C 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、-S(O) p R ba 、-N=S(O)R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or two R's attached to the same carbon x8 Together they form a 3- to 8-membered cycloalkyl or a 3- to 8-membered heterocyclic group; the 3- to 8-membered cycloalkyl or the 3- to 8-membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; x 9 Selected from CR x9 、N、O、NR x9 、S(O) p , CR x9 R x9 , C(=CR x8 ), where R x9 is the same or different at each occurrence and is independently selected from H, deuterium, halogen, hydroxyl, -NR n1 R n2 , cyano, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb and -C(O)NR bc R bd ; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or two R's attached to the same carbon x9 Together they form a 3 to 8-membered cycloalkyl or a 3 to 8-membered heterocyclic group; the 3 to 8-membered cycloalkyl and the 3 to 8-membered heterocyclic group are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R x8 With R x9 and the atoms to which it is connected together form a 3- to 7-membered ring; the 3- to 7-membered ring is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , deuterated C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 The 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR n1 R n2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 , -C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; is a single bond or a double bond; R a , R d and R e are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR n1 R n2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1-6 Alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; or R a , R d and R e Any two atoms connected to the 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl together form a 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl; wherein the 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; W is selected from Ring B is selected from 3- to 10-membered cycloalkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, 5- to 7-membered monoheterocyclyl, 7- to 12-membered spiroheterocyclyl, 6- to 10-membered bridged heterocyclyl, and 6- to 10-membered fused heterocyclyl; Each R b are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, -NR n1 R n2 , -C 1-6 Alkoxy C 1-6 alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -OR f 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd 、S(O) p NR be R bf and S(O) p R ba ; wherein said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, -C 1-6 Alkoxy C 1- 6-membered alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; the 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C 1-6 The alkyl group is substituted by one or more substituents; R n1 , R n2 , R a1 , R a2 are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy 1-6 Alkyl, -OR f 、-C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein the C 1-6 The alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl groups are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, amino, nitro, hydroxyl and hydroxyl C 1-6 The alkyl group is substituted by one or more substituents; R ba , R bb , R bc , R bd , R be , R bf are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, hydroxy 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Deuterated alkoxy, C 1-6 alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein the C 1-6 The alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl groups are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, -OR f 、-C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , cyano, -NR a1 R a2 , nitro, hydroxyl and hydroxyl C 1-6 The alkyl group is substituted by one or more substituents; or R n1 With R n2 , R a1 With R a2 , R bc With R bd , R be With R bf Together with the nitrogen atom to which they are attached, they form a 3-7 membered heterocyclic group; the 3-7 membered heterocyclic group is optionally selected from deuterium, halogen, C 1-6 Alkyl, deuterated C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 substituted by one or more substituents selected from alkyl, 3- to 8-membered cycloalkyl, 3- to 8-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; Ring C is selected from 3- to 10-membered cycloalkyl, 3- to 10-membered heterocyclyl, 6- to 10-membered aryl, and 5- to 10-membered heteroaryl; Each R c are the same or different and are each independently selected from hydrogen, deuterium, halogen, C 1-6 Alkyl, cyano, -NR n1 R n2 , hydroxyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, -C 1-6 Alkoxy C 1-6 Alkyl, -C(O)R ba 、S(O) p R ba 、S(O) p NR be R bf 、-C(O)OR bb 、-C(O)NR bc R bd , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein the C 1-6 The alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl groups are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, hydroxy C 1-6 Alkyl, -C(O)R ba1 、S(O) p R ba1 、S(O) p NR be1 R bf1 、-C(O)OR bb1 、-C(O)NR bc1 R bd1 , 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; the 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl are optionally substituted by one or more substituents selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxy, -C(O)R ba2 、S(O) p R ba2 、S(O) p NR be2 R bf2 、-C(O)OR bb2 、-C(O)NR bc2 R bd2 and hydroxy C 1-6 The alkyl group is substituted by one or more substituents; R ba1 , R bb1 , R bc1 , R bd1 , R be1 , R bf1 , R ba2 , R bb2 , R bc2 , R bd2 , R be2 , R bf2 are the same or different and are each independently selected from hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 deuterated alkoxy, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein the C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclic group, 6 to 10 membered aryl and 5 to 10 membered The membered heteroaryl group is optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1-6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, cyano, -NR a1 R a2 、-OR f , nitro, hydroxyl and hydroxyl C 1-6 The alkyl group is substituted by one or more substituents; R f Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl; wherein the C 1-6 The alkyl, 3 to 8 membered cycloalkyl, 3 to 8 membered heterocyclyl, 6 to 10 membered aryl and 5 to 10 membered heteroaryl groups are optionally selected from deuterium, halogen, C 1-6 Alkyl, oxo, C 2-6 Alkenyl, C 2-6 Alkynyl, halo C 2-6 Alkenyl, halogenated C 2-6 Alkynyl, C 1- 6 Alkoxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, deuterated C 1-6 Alkyl, deuterated C 1-6 Alkoxy, cyano, -NR a1 R a2 , nitro, hydroxyl and hydroxyl C 1-6 The alkyl group is substituted by one or more substituents; n is selected from 0, 1, 2 or 3; m is selected from 0, 1, 2 or 3; p is selected from 0, 1 or 2.

2. The compound according to claim 1 and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, wherein R d and R e The atoms to which it is attached together form a 3- to 6-membered cycloalkyl group or a 3- to 6-membered heterocyclic group.

3. The compound according to claim 1 or 2 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein R d and R e The atoms to which it is connected together form a cyclopropyl group or an oxetanyl group.

4. The compound according to at least one of claims 1 to 3 and its pharmaceutically acceptable salt, or its stereoisomer, or its prodrug, or its nitrogen oxide, or its solvate, or its isotopic derivative, which is a compound represented by formula (I) and its pharmaceutically acceptable salt, or its stereoisomer, in, Ring B, Ring C, R b , R a , R c ,m,n,W,x 1 to x 9 As defined in at least one of claims 1 to 3.

5. The compound according to at least one of claims 1 to 4 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein ring C is a 5-membered heteroaryl group, each R c The same or different, and each independently is C 1-6 Preferably, ring C is R c Selected from -CHF2.

6. The compound and pharmaceutically acceptable salt thereof, or stereoisomer thereof, or prodrug thereof, or nitrogen oxide thereof, or solvate thereof, or isotopic derivative thereof according to at least one of claims 1 to 5, which is a compound represented by formula (II) and pharmaceutically acceptable salt thereof, or stereoisomer thereof, or prodrug thereof, or nitrogen oxide thereof, or solvate thereof, or isotopic derivative thereof: in: x 1 、x 2 、x 3 、x 4 、x 5 、x 6 、x 7 、x 8 、x 9 , Ring B, R b , R a , n as defined in at least one of claims 1 to 5.

7. The compound according to at least one of claims 1 to 6 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein R a is selected from -CH3, -CH2F, -CN, -CH2=CHF, -CHF2, -CHF3, -CD3; preferably, R a Selected from -CH3, -CH2F, -CN.

8. The compound according to at least one of claims 1 to 7 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein ring B is selected from 9. A compound as claimed in at least one of claims 1 to 8 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein Selected from R b1 , R b2 , R b3 are the same or different and are each independently selected from R b , R b As defined in at least one of claims 1 to 8; preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R b2 and R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R ba , R bb , R bc , R bd , R be , R bf As defined in at least one of claims 1 to 8; further preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R b2 and R b3 are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, R ba , R bb , R bc , R bd , R be , R bf As defined in at least one of claims 1 to 8; further preferably, Selected from R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxy C 1- 6-alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R ba , R bb , R bc , R bd , R be , R bf As defined in at least one of claims 1 to 8; most preferably, Selected from R b1 Selected from hydrogen, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba , R ba , R bb , R bc , R bd , R be , R bf are the same or different and are each independently selected from hydrogen, C 1-6 Alkyl, 3 to 8 membered heterocyclic group, halogenated C 1-6 Alkyl, hydroxy C 1-6 Alkyl, deuterated C 1-6 Alkyl, 3 to 8 membered cycloalkyl, C 1-6 Alkoxy, C 2-6 alkenyl, 5 to 6 membered heteroaryl; wherein the C 1-6 Alkyl, 3 to 8 membered heterocyclyl, 3 to 8 membered cycloalkyl, 5 to 6 membered heteroaryl are optionally selected from C 1-6 Alkyl, halogen, deuterated C 1-6 Alkyl, halogenated C 1-6 Alkyl, hydroxyl, C 1- 6-alkoxy, deuterated C 1-6 Alkoxy, -C(O)OR bb1 、-NR a1 R a2 ; R bb1 , R a1 , R a2 As defined in at least one of claims 1 to 8.

10. The compound according to at least one of claims 1 to 9 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein each R b , R b1 are the same or different and are each independently selected from hydrogen, Methyl, vinyl, ethynyl, 11. A compound according to at least one of claims 1 to 10 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein Selected from 12. A compound according to at least one of claims 1 to 11 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein: Structural unit Selected from Among them, ring J, ring J 1 、Ring J 2 、Ring J 3 、Ring J 4 、Ring J 5 、Ring J 6 、Ring K 1 、Ring K 2 and ring K are the same or different and are each independently an optionally substituted 3-7 membered ring, R x2 , R x6 , R x8 , R x9 As defined in at least one of claims 1 to 14; preferably, the structural unit Selected from 13. A compound according to at least one of claims 1 to 12 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, which is a compound represented by formula (II-1B), formula (II-1C), formula (II-2B), or formula (II-2C) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof: in: R b1 Selected from hydrogen, C 1-6 Alkyl, hydroxyl C 1-6 Alkyl, 3- to 8-membered heterocyclic group, -S(O)2R ba 、-C(O)R ba 、-C(O)OR bb 、-C(O)NR bc R bd , optional C 1-6 alkyl-substituted 5- to 6-membered heteroaryl, S(O)2NR be R bf 、-S(O)R ba ;R a 、 R x2 , R x6 , R x8 , R x9 , R ba , R bb , R bc , R bd , R be , R bf As defined in at least one of claims 1 to 12.

14. A compound according to at least one of claims 1 to 13 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, which is a compound represented by formula (II-2K), formula (II-2L), or formula (II-2M) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof: in: is a single bond or a double bond; x 4 、x 5 、x 7 are the same or different and are each independently selected from N or C; x 9 is selected from N or CH; And x 4 、x 5 、x 7 、x 9 The ring where it is located is an aromatic ring; R b1 Selected from R b ; R b , R a As defined in at least one of claims 1 to 13.

15. A compound according to at least one of claims 1 to 14 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, which is a compound represented by formula (II-3A) and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof: in: is a single bond or a double bond; x 4 、x 5 、x 7 、x 8 、x 9 are the same or different and are each independently selected from N or C; and x 4 、x 5 、x 7 、x 8 、x 9 The ring where it is located is an aromatic ring; Ring J 7 is selected from 5- to 10-membered heteroaryl or 3- to 8-membered heterocyclyl; q is selected from 0, 1 or 2; R b1 Selected from R b ; R b , R a , R x8 As defined in at least one of claims 1 to 14.

16. The compound according to at least one of claims 1 to 15 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein Ring J, Ring J 1 、Ring J 2 、Ring J 3 、Ring J 4 、Ring J 5 、Ring J 6 、Ring J 7 、Ring K 1 、Ring K 2 and Ring K are the same as or different from each other and are each independently a 3-7 membered ring, preferably a 5- to 10-membered heteroaryl group or a 3- to 8-membered heterocyclic group, more preferably a 5- to 10-membered heteroaryl group, further preferably a 5- to 6-membered nitrogen-containing heteroaryl group, and most preferably a 5-membered nitrogen-containing heteroaryl group.

17. The compound according to at least one of claims 1 to 16 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein R x8 are the same or different at each occurrence and are each independently selected from hydrogen, deuterium, methyl, amino, methoxy, Oxo, Cl, F, ethyl, trifluoromethyl, isopropyl, cyclopropyl, 18. The compound according to at least one of claims 1 to 17 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein R x9 is selected from methyl, ethyl, isopropyl, cyclopropyl, -CH2CF3, Methoxy, 19. The compound according to at least one of claims 1 to 18 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein R ba , R bb , R bc , R bd , R be , R bf are the same or different and are each independently selected from hydrogen, methyl, -CD3, isopropyl, tert-butyl, Methoxy, tert-butoxy, 20. The compound according to at least one of claims 1 to 19 and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein R b1 is the same or different at each occurrence and is each independently selected from hydrogen.

21. A compound and a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, wherein the compound is selected from any of the following compounds:

22. A pharmaceutical composition comprising a compound according to at least one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, and a pharmaceutically acceptable carrier.

23. Use of at least one compound according to claims 1 to 21 or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, or a pharmaceutical composition according to claim 22 in the preparation of a medicament for treating PARG-mediated cancer.

24. A method for treating PARG-mediated cancer, comprising administering to a patient a therapeutically effective amount of a compound according to at least one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a prodrug thereof, or a nitrogen oxide thereof, or a solvate thereof, or an isotopic derivative thereof, or a pharmaceutical composition according to claim 22.

25. The use according to claim 23 or the method according to claim 24, wherein the cancer is selected from ovarian cancer, pancreatic cancer, breast cancer, prostate cancer.

Images